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Abstract
Most breast cancer related deaths are caused by the spread or metastasis of the primary tumor
to distant sites in the body. The lymph nodes are one of the first places where metastases can
be detected and are frequently examined for macroscopic metastases to help determine
course of treatment for patients. However, little is known about the significance of
microscopic metastases and disseminated individual cancer cells within the nodes. The goal
of this work was to use MRI to monitor the development of primary tumors and lymphatic
metastases in models of breast cancer.
In this thesis, we examined the MRI appearance of lymph nodes in several different strains of
immune compromised mice (nude, CB -17 SCID, NOD/SCID IL2Rnull) and compared the
appearance to immune competent C57/Bl6 strain. We found that immune deficiencies
influenced the MRI appearance of nodes and that the nude strain had highly variable lymph
node appearance and volume. We also compared orthotopic transplantation models of breast
cancer that used both the nude and CB-17 SCID strains using MRI. We found that MRI was
most reliable for detecting metastases in the lymph nodes of SCID mice and that the
variability of the appearance of nodes in nude mice can lead to their misclassification. We
then used the SCID orthotopic breast cancer model to monitor the appearance and retention
of iron oxide nanoparticle labeled cancer cells in both the primary tumor and lymph nodes.
We found that iron-labeled cells are still detected within the primary tumor after 28 days
post-implantation and that these labeled cells almost exclusively migrated to the lymph
nodes.
The development of improved methods for monitoring the development of the primary tumor
and metastases and the roles that different cells populations have in these processes will
allow for more accurate knowledge of how cancer cell heterogeneity impacts disease
progression. These tools will allow for more effective monitoring of the treatment effect of
new drugs on primary tumors and metastatic dissemination.
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Chapter 1

1

General Introduction

Cancer is one of the most devastating conditions that a patient can be faced with. Even
though tremendous progress in the understanding and treatment of cancer has been made
throughout the last few decades, many patients will still suffer severe morbidity and
mortality, mostly due to late stage metastatic disease. By improving our understanding of the
processes and cell phenotypes involved in metastasis, the prognosis for patients diagnosed
with cancer could be dramatically improved. Cellular MRI is a technique that can be used to
detect and monitor cells in vivo and may allow the metastatic process and the characteristics
of the tumor cells that are involved to be studied in greater detail. This introductory chapter
will discuss the concepts of breast cancer, metastasis, tumor heterogeneity and cellular
dormancy as well as the techniques used in cellular MRI and how this technology is currently
used in research.

1.1

Cancer

Approximately 186,400 people were diagnosed with all types of cancer in Canada in the year
2012 with an estimated 75,700 patient deaths attributable to the disease.1 Cancer is defined as
uncontrolled growth of abnormal cells resulting in life-threatening disease.2 Clinically,
cancer is considered to be collection of disorders involving unregulated cell growth,
combined with invasion into surrounding tissues and spread to other organs.2 This clinical
definition of cancer, however, does not consider all aspects of tumorigenesis and the cellular
processes that become deregulated. The definition includes many generalizations and does
not account for differences between tumor types and how these differences impact treatment
and outcomes.2 In reality, there is great diversity between cancers in different patients, even
if these diseases are of the same tumor type.2 Cancer is an extremely complex set of diseases
that requires the deregulation of normal homeostasis pathways and the acquisition of
characteristics – such as resisting cell death, inducing angiogenesis, sustained proliferative
signaling, replicative immortality, invasion and metastasis and evading growth suppression –
that provide a survival advantage.3,4 Hanahan and Weinberg describe these characteristics, or
1

2

hallmarks of cancer, and the implications they may have for new therapy development.4 They
also describe emerging hallmarks that have been identified more recently and are now
recognized as necessary for tumor growth and progression.4 These emerging hallmarks
include: tumor promoting inflammation, deregulated cellular metabolism, genomic instability
and evading immune distruction.4 More recent studies have also identified the tumor
microenvironment as playing a major role in the development and progression of many
tumors by supporting the changes that occur to produce these hallmarks and will be further
discussed in section 1.1.3.5,6

1.1.1

Breast Cancer

In 2012, breast cancer was estimated to be the most common cancer diagnosed among
women in Canada and had the second highest mortality rate, only behind lung cancer.1Breast
cancer consists of many different diseases. These cancers typically arise in the lobules or
ducts of breast tissue and the histological designation indicates the location and structure of
the resulting tumor.7Table 1.1 lists different histological types of breast cancer as well as
their frequency.7

Table 1.1 – Histological breast tumor type and frequency7,8
Tumor Type

Frequency

Invasive Ductal Carcinoma, Not otherwise specified

75 %

Invasive Lobular Carcinoma

10 %

All other types – medullary, neuroendocrine, tubular, apocrine, <10%
metaplastic, mucinous (A and B), inflammatory, comedo,
adenoid cystic and micropapillary

2

3

Breast cancers can also be classified according to their expression of certain markers such as
the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor
receptor (HER2).8,9 The expression of these markers has been shown to correlate with the
histological type.8 For example, studies have shown that invasive lobular carcinomas are
more likely to be hormone receptor positive compared to ductal carcinomas.8,10 Arpino et al.
have also shown that lobular carcinomas are more likely to be HER2 negative compared to
ductal carcinomas.10
Breast cancer classification based on marker expression is shown in Table 1.2. This
classification is different from the histological typing and attempts to account for the
different tumor characteristics observed with the expression of these markers.11 The
expression of these markers also affects treatment options and patient prognosis.7,9 Patients
with triple negative tumors – no ER, PR or HER2 expression – typically have the poorest
prognosis of all breast cancer patients, while patients with only ER expression in their tumors
typically have the best prognosis.7

Table 1.2 - Expression of prognostic markers in different breast cancer subtypes.11
Breast Cancer Subtype

Markers Expressed

Luminal A

ER and/or PR, low proliferation

Luminal B

ER and/or PR, high proliferation
ER and/or PR, HER2

HER2 Positive

HER2

Triple Negative

No markers expressed

3

4

1.1.2

Metastatic Process

Most patients do not die from the primary tumor, but rather the metastases that develop.12
Metastasis is the process through which cancer cells are able to migrate from the site of the
primary tumor to distant sites within the body and develop secondary tumors.13 This process
can occur through several different routes, including the blood and lymphatic system and
even through body spaces.14 The metastatic process involves 5 steps: (1) detachment from the
primary tumor, (2) intravasation into blood or lymphatic vessels, (3) arrest at a distant site,
(4) extravasation into the new site and (5) growth within the new site, forming a secondary
tumor.14 Figure 1.1 depicts the steps in metastatic process.

Figure 1.1 - Steps in the metastatic process. (1) Cells detach from primary tumor. (2)
Cells intravasate into vessel. (3) Cells arrest at a distant site. (4) Cells extravasate from
vessel at distant site. (5) Cells proliferate, forming a clinically detectable secondary
tumor.
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However, metastasis is an inefficient process.12,13,15 The majority of cells that leave the
primary tumor are unable to form metastases in a new, distant site.13 Once cancer cells arrive
at a new site, they can undergo one of three possible fates. They can either die through
apoptosis, proliferate to form metastasis or remain in a dormant state.15
In breast cancer, distant metastases most commonly occur in the liver, lung, brain and bone.15
The presence of metastases at these sites at diagnosis greatly reduces the likelihood of
survival. Metastases to the regional lymph nodes also occurs frequently and the presence of
metastases in the sentinel lymph node, which is the first node or set of nodes that drains the
region of the primary tumor, has a great prognostic value and is biopsied in the clinic to
assess a patient’s potential outcome.16 These sentinel lymph nodes are routinely biopsied in
breast cancer and examined for evidence of disseminated cells.16–20 The presence of
metastasis in the sentinel lymph node is the best indicator of survival and is independent of
tumor volume.21

1.1.2.1

Structure and Function of The Lymphatic System

The lymphatic system is an important part of the immune system and also facilitates the
return of interstitial fluid to the circulatory system. This system consists of a network of
vessels that allow easy access to cells and fluid (or lymph) and lymph nodes that facilitate the
immune response. Lymph passes through the nodes where it is monitored for the presence of
pathogens. Immune cells can also migrate through this system, such as macrophages,
dendritic cells and lymphocytes.
The lymph nodes are secondary lymphoid organs.22,23 They contain T cells, which occupy the
paracortex, and B cells, which occupy the cortex; specifically the follicles and germinal
centers.23 The medulla, which is near the center of the lymph node, primarily consists of
plasma cells and B cells.22 These immune cells are supported by a variety of stromal cells,
which include endothelial cells, fibroblastic reticular cells and follicular dendritic cells that
produce various chemokines including CCL19, CCL21, CXCL12 and CXCL13, which
attract immune cells to the node.23 The nodes also have a dedicated blood supply where
immune cells can also enter the node to participate in the immune response.22
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Afferent lymph enters the node at the outer capsule,22,24 where antigens can be presented to T
cells by dendritic cells, activating an immune response. Lymph fluid that enters the node then
continues to travel towards the center of the node, or medulla, where the efferent vessel
allows the lymph to continue on to the next node or the thoracic duct.22,24 Figure 1.2 shows
the structure of the lymph node and the location of the various immune cells.

Figure 1.2 - Schematic of lymph node depicting the location of immune cells and
various structures. Adapted from reference 22.

1.1.2.2

Role of Lymph Node Metastases in Disease Progression

Metastases from lymphatic vessels will typically occur in the region directly under the lymph
node capsule, since this is the first area where disseminated cells will arrest.25 Cells that
arrive in the lymph node via the blood can potentially arrest anywhere in the node. The
cancer cells can then go on to grow in and engulf the node or metastasize to new sites.
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Metastases in the lymph nodes can cause further spread through two different routes, either
the lymphatic system or through the lymph node vascular supply.16 Breast tumor cells are
also known to express CXCR4 which is the receptor for CXCL12, which promotes tumor
growth and metastases to lymph nodes.16,26,27 CXCR4 has also been implicated in the
metastasis of hepatocellular carcinoma to the lymph nodes in patients.28
Lymphangiogenesis, the growth of new lymphatic vessels, near the primary tumor and within
lymph nodes has also been observed in experimental models and in clinical cases.29,30 This
process may actually precede the dissemination of tumor cells to the lymph nodes and
VEGF-C and VEGF-D have been implicated in this process.16,29,31
There is some controversy about what the significance of micrometastases (lesions between
0.2 and 2 mm) and isolated tumor cells (lesions < 0.2 mm) detected in the sentinel lymph
node is on the prognosis of the patient.32It has been reported that breast cancer patients with
micrometastases in the sentinel lymph node have a 5% to 25% incidence of metastases in a
non-sentinel lymph nodes, while patients with macroscopic metastases in the sentinel node
have an incidence of 40% to 60%.33

1.1.3

Tumor Microenvironment and Heterogeneity

Tumors do not consist of only cancer cells. There are many different types of host cells that
are part of the tumor which form the stroma that supports the survival and growth of the
cancer cells. The stroma can include fibroblasts, mesenchymal stem cells, macrophages,
various immune cells (eg. T-cells and neutrophils), and even adipocytes.26 These cells
interact with the transformed cancer cells through various cytokines and growth factors,
creating an environment that supports the growth of the tumor.26 These stromal cells, are also
able to regulate the extracellular matrix which creates an environment that promotes altered
metabolism, invasiveness and decreased apoptosis.34 All these cancer-stroma interactions
contribute to the development of the various hallmarks of cancer and cause tumors to be very
complicated systems.35
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Figure 1.3 – The tumor microenvironment. There are many different types of cells
within a tumor, some of which support the growth and survival of cancer cells through
cellular interactions. Adapted from reference 26.

Even though there are a wide variety of cells within a tumor, the transformed cancer cells
themselves are also heterogeneous in their phenotype and behavior including invasiveness
and metastatic potential.36 Some cancer cells will be more proliferative than others and the
expression of particular surface markers or enzymes will also vary. For example in breast
cancer, tumors can be classified as basal or luminal, but will have populations of cancer cells
that have phenotypes from both classes.36
There are two different theories that attempt to explain the heterogeneity observed within
populations of tumor cells, one is the clonal evolution model and the other is the hierarchical
model.37–39 In the clonal evolution model, different subpopulations are generated by random
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mutations that occur within the cells, enabling some populations to be more invasive while
hindering the survival of others.37–39 In the hierarchical model, the diversity within the tumor
is due to a stem cell like structure similar to those found in normal tissues.37 At the top of the
hierarchy is the cancer stem cell (CSC), or tumor initiating cell, which is capable of self
renewal and producing progeny of the cellular subtypes within the tumor cell population.37–40
CSCs are discussed in section 1.1.5.3. In reality, both of these models of heterogeneity exist
within a tumor, with the impact of each varying between tumors types.37,38,40 This allows
multiple populations to survive within a tumor and can affect the tumor’s resistance to certain
therapeutics.
The tumor will also evolve over time and have many different subpopulations that will
appear and disappear due to acquired mutations that can impact the success of treatment.
Studies of cancer cells using dyes such as BrdU and CFSE have revealed that there is
heterogeneity in the retention of these labels over time in breast cancer,41,42 gastrointestinal
cancer43 and head and neck cancers, highlighting the existence of multiple cancer cell
populations with different cycling times, which impacts the effectiveness of current
therapies.44 These studies have shown that there is a difference in how these label-retaining
cells respond to chemotherapy; Moore et al. showed a increase in the percentage of labelretaining cells following treatment with oxaliplatin, 5-fluorouracil or combination of the two
drugs.41

1.1.4

Dormancy

Dormancy is defined as a state in where minimal disease, such as single cells or
micrometastases exists, and remains clinically undetectable for extended periods of time.45
These cells are thought to be able to persist in this dormant state for long periods of time,
only to be triggered to proliferated by unknown signals.15,46,47 Dormancy is frequently
observed in breast cancer as well as many other tumor types.48 Patients will be treated
successfully for the primary tumor, only to experience recurrence at a much later time, from
a few years to over a decade.47,49 These dormant cancer cells are much more difficult to treat
since many available therapies target actively dividing cells and the outcome tends to be
worse for patients who experience recurrence after a period of dormancy.50
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Dormancy can be divided into cellular and tumor dormancy. Each of these processes can
occur during metastasis, with the amount of cells progressing from cellular dormancy to
micrometastases, and the number of micrometastases progressing from tumor dormancy to
secondary tumors, dramatically decreasing at each stage.47,49,51–53 Figure 1.4, which is
adapted from work in Dr. Ann Chambers lab, shows the later stages of the metastatic process
and the percentage of cells that are predicted to progress from each stage to the next, as well
as the percentage that remain dormant at each stage. These processes involve different
mechanisms for maintaining as well as escaping from dormancy.

Figure 1.4 – Dormancy and inefficiency of metastatic process. Only a small percentage
of the tumor cells that arrest at a second site will go on to form micrometastases and
macrometastases. The majority of cells will undergo apoptosis or will remain in a
dormant state. Less than 2 % of arrested cells will form micrometastases and less than
0.02% of those micrometastases will develop into macrometastases in experimental
metastasis models. The question marks in the figure represent quantities that are
unknown. The number of cells that will enter a dormant state after arrest is not known
as well as the percentage of dormant cells or micrometastases that develop into
macrometastases. Adapted from reference 15.
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1.1.4.1

Tumor Dormancy

A primary tumor or a micrometastasis can remain undetectable for a long period of time.
This type of dormancy is defined as having near equal amounts of proliferation and cell death
occurring within the tumor mass.15 This balance of proliferation and cell death may be due to
the fact the new tumor has not yet been able to escape the limits that are placed on it by the
immune system, nutrient supply and microenvironment.15,46,50 The number of tumors or
metastases that escape dormancy is low, with most remaining clinical undetectable and
asymptomatic potentially for decades.50,54,55

1.1.4.2

Dormancy of Single Cancer Cells

Cells that leave the primary tumor and arrest at a new site can remain dormant, die or
proliferate. Studies have shown that single disseminated cells in an experimental metastasis
model can co-exist with micro- and macro-metastases.49,51–53 These single cells have been
found to be viable and not actively undergoing cell division (low Ki67 expression).49,51,53
Townson et al. and Heyn et al. have used iron oxide nanoparticles to label and track the
development of metastatic lesions and the persistence of non-proliferative cancer cells in
experimental melanoma and breast cancer metastasis models.47,52 Naumov et al. have used
fluorescent nanoparticles to track the location of dormant tumor cells in an experimental
breast cancer metastasis model.49 Using intravital videomicroscopy, they showed that solitary
label retaining cancer cells could be detected in the liver in situ that were not actively
proliferating or undergoing apoptosis.49 Other studies have investigated the mechanism that
might be maintaining the dormant population and potentially allowing cells to escape
dormancy, and have suggested that signals from the extracellular matrix interacting through
integrins may be a factor in regulating both maintenance and escape.46,56
It has been suggested that dormant tumor cells may also be resistant to treatments that target
actively dividing cells. Towson et al. demonstrated that chemotherapeutics have little effect
on dormant, or label retaining cells.52 They found that while treatment with doxorubicin had
a significant effect on metastasis volume, it did not impact the number of non-proliferative
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cells that could be detected within MR images of the liver.52 Ranganathan et al. have also
shown that increased p38 signaling induces dormancy and resistance to etoposide and
doxorubicin in a human epidermoid carcinoma cell line.57

1.1.4.3

Cancer Stem Cells

Cancer stem cells (CSC) or tumor initiating cells are a subset of tumor cells that are able to
form tumors and potentially metastases.37,39,40,58 These cells possess characteristics similar to
normal stem cells, which include slow proliferation, increased resistance to chemotherapeutic
drugs, unlimited proliferative potential, the ability to differentiate into all tumor cell
subpopulations and use of similar signaling pathways.40,58
Functionally, these cells have been defined through limiting dilution assays conducted in
various strains of immune compromised mice.37 In these assays, cells are sorted by flow
cytometry into tumorigenic and non-tumorigenic populations. Bonnet and Dick determined
that cells that were both CD34 positive and CD38 negative were capable of initiating
leukemia in NOD/SCID mice59 while Al-Hajj et al. determined that tumor growth could be
initiated by cells that were CD44 positive, CD24 negative and ESA positive.60 Other markers
have been identified for other tumor types, for example, CD133 for colon, prostate and
potentially lung cancer61–63 and CD133 and nestin for glioma.64,65 High expression of other
markers such as aldehyde dehydrogenase (ALDH), integrin alpha 6 (CD49f) and CD133
have also been reported as being markers of breast CSCs.66–68 However, defining these
populations based on surface markers may not be the most effective method for
identification. These markers may vary between patients and multiple stem-like populations
may exist in one tumor.37 Identifying these cells using functional markers, such as the
retention of a label or the activation of specific enzymes, may be more effective.
Recent work suggests that CSCs may actually play a role in the dormancy of single cells.15
The observation of slow progression through the cell cycle, or non-proliferation (extended
G0/G1), is a feature of normal stem cells that can also be characteristic of certain CSC
populations.40,69,70 Recently, studies of label retaining cancer cells have shown that these cells
may possess stem-like characteristics and are capable of initiating tumor growth.43 Some
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studies also show that a specific subset of CSCs may be responsible for metastasis.

66,71,72

Other work has shown that the Epithelial to Mesenchymal Transition (EMT) may also
generate cells with a stem-like phenotype and may be needed for CSCs to metastasize.73,74
The role that CSCs play in tumor progression, dormancy and metastasis still needs to be
elucidated and only then will the full impact of this population on disease progression be
understood.
In order to gain a better understanding of metastasis, cellular dormancy and the role that
CSCs or tumor initiating cells and the microenvironment may play in these processes, new
techniques need to be developed that allow for these concepts to be studied in vivo over time
and therapeutic approaches to be validated. Cellular MRI is a technique that may allow for
these processes to studied non-invasively and help push our knowledge forward on these
subjects.

1.2

Cellular MRI

Cellular MRI is an imaging technique that incorporates high resolution MRI and cells labeled
with contrast agents to visualize the location and behavior of these cells in vivo. The
following sections give a brief description of basic MRI principles, pulse sequences, contrast
agents and the principles and applications of cellular MRI.

1.2.1

Nuclear Magnetic Resonance (NMR)

Magnetic resonance imaging can be accomplished due to the intrinsic property of subatomic
particles called spin (or the intrinsic angular momentum of the particle).75,76 All protons,
neutrons and electrons have a non-zero value of spin. For the purpose of this work, protons
will be the main particle discussed.
Both the proton and neutron have a spin equal to ½. In nuclei with multiple protons and
neutrons, the spin of the entire nucleus will be a sum of the spins from all unpaired protons
and neutrons. Nuclei with a non-zero spin will have a magnetic dipole and have a magnetic
moment.75
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When a proton, which has a spin of ½, is exposed to a magnetic field, it will experience a
force that will cause it to align with the field. However, the proton will not align completely
and will precess about an axis that is parallel with the applied field. The frequency of the
proton’s precession or the Larmor frequency, ωo, in an external magnetic field, B0, is given
by the following equation76:
!! = !!!!!
Where γ is the gyromagnetic ratio, which is 42.57 MHz/T for a proton.76 When an external
magnetic field is applied to a volume containing many protons, as is the case in MRI, a net
magnetization is produced within the volume that aligns with the magnetic field.75,76 In the
volume, not all of the protons will precess around a direction that will constructively add to
the net magnetization, but will precess in a way that reduces the size of the magnetization
available for imaging. This is dependent on both the magnetic field strength and the
temperature of the volume. The magnitude of the net magnetization, M0, is given by the
following equation76:
!! ! ℏ! !!
!! =
4!!"
Where ρ is the density of protons within the volume, ħ is Planck’s constant divided by 2π, k
is Boltzmann’s constant and T is absolute temperature. When an MRI image is acquired, an
oscillating magnetic field, B1, is applied to the volume in addition to B0, exciting the
protons.75 This causes magnetization to tip from the z-axis, which is parallel to B0, into the
transverse plane perpendicular to B0.75,76 The magnetization will then gradually return to its
original orientation parallel to the z-axis once B1 has been switched off.76 The signal
measured by the imaging system during acquisition is the relaxation of the magnetization
back to the equilibrium state.75,76 During the acquisition process, a series of magnetic field
gradients in different spatial directions are applied to encode different frequencies and phases
to different areas of the volume, allowing for the location of specific signals to be
determined.76,77
The signal is detected due to the precession of the magnetization in the transverse plane. This
induces a varying voltage and current in a coil that is placed nearby for detection. The
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magnetization as a function of time in the z-axis and transverse plane is given by the
following equations.76
!! = ! !! (1 − !
!!" = !! !

!!

!!

!! )

!!

Where T1 and T2 are relaxation time constants that describe how the magnetization within a
volume will return to equilibrium. These constants are known as spin-lattice and spin-spin
relaxation, respectively, and vary between tissues. These time constants are discussed in
sections 1.2.2.

1.2.2

T1 and T2 Relaxation

The process of relaxation involves two different mechanisms: T1 relaxation and T2
relaxation.75 These mechanisms are extremely important in determining image contrast and
affect the choice of pulse sequence used for imaging. The relaxation constants vary between
tissues and will also change in the presence of disease.76 Table 1.3 shows the normal T1 and
T2 relaxation times for different tissues at 1.5T.
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Table 1.3 - Approximate values of relaxation times at 1.5 T 77
Tissue

T1 (ms)

T2 (ms)

Grey matter

920

101

White matter

790

92

Cerebrospinal fluid (CSF)

2650

280

Kidney

650

58

Liver

490

43

Skeletal muscle

870

47

T1, or spin-lattice relaxation, refers to the transfer of energy from the excited protons to other
elements within the immediate surroundings. These include other molecules and nuclei that
possess a magnetic moment.
The longitudinal magnetization, MZ, will recovery as an inverse exponential, becoming
asymptotic as it reaches its original pre-excitation value. The T1 relaxation time is defined as
the time for the magnetization to return to 63% of the pre-excitation value along the
longitudinal or z-axis.

75,76

Figure 1.5 shows the recovery of the longitudinal magnetization

and decay of the transverse magnetization.
T2, or spin-spin relaxation, refers to the interactions within the pool of protons that is
available for imaging. When protons are in close proximity of each other, each proton will
induce a slight shift in the main magnetic field that other protons will experience. This causes
the protons to precess at frequencies that are slightly above and below the Larmor frequency,
inducing dephasing in the transverse plane. During this process, there is no net transfer of
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energy outside of the system. Transfer of energy outside of the system only occurs during T1
relaxation.76,78
The transverse magnetization, MXY, will decay exponentially until it reaches a value of 0, as
shown in Figure 1.5. The T2 relaxation time is defined as the amount of time for the
transverse magnetization to decay to 37% of the original value in the transverse plane.75,76 T2
relaxation occurs much more quickly than T1 relaxation, with T2 values typically 10 times
shorter than T1 values.

Figure 1.5 - Relaxation curves for transverse (MXY, black) and longitudinal (MZ, blue)
magnetization. Adapted from reference 76.

Both T1 and T2 relaxation times are dependent on the strength of B0. All molecules in a
tissue will be moving at different frequencies, which can be described by the spectral density
function. Exchange can only occur between excited protons and surroundings that are at the
same frequency on the spectral density function. As the frequency increases, the amount of
protons or other nuclei moving at that frequency decreases. Because of this effect, T1 will
increase as B0 increases since there are fewer protons available in the surroundings for
17
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exchange, requiring more interactions with the surroundings to dissipate the magnetization
and therefore more time.76
Increasing B0 has a smaller effect on T2 relaxation times.76,78 There is an increase in field
inhomogeneities with increasing B0 that affects the apparent T2 relaxation time (T2*). The
T2* relaxation time accounts for both T2 effects and field inhomogeneities and will shorten
as the field strength increases.

1.2.3

Pulse Sequences

Pulse sequences consist of a series of timed applications of spatial field gradients and
radiofrequency (RF) pulses that are used to measure the signal produced from excitation.
There are two main timing parameters: TR, or the repetition time, and TE, or the echo time.
TR represents the amount of time from one RF excitation pulse to the next RF excitation
pulse in the next repetition of the pulse sequence. TE is the time from the RF excitation pulse
to the echo of the signal. The signal echo can be produced by either an RF pulse or gradient
pulse, allowing sequences to be classified as spin echo or gradient echo type, depending on
which of these methods is used.76

1.2.3.1

Spin Echo Sequences

Spin echo (SE) sequences consist of a 90o RF pulse followed by a 180o RF pulse at time
TE/2. The 180o RF pulse refocuses the spins, which are dephasing prior to the pulse. A
timing diagram of a basic SE sequence is shown in Figure 1.6.
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Figure 1.6 - Single spin echo sequence timing diagram. Adapted from reference 75.

By adjusting TR and TE, different contrasts can be generated with a SE sequence, including
T1 weighted, T2 weighted and proton density weighted. Table 1.4 shows how these
parameters can be adjusted to generate these contrasts. Some common SE sequences include:
Single spin echo, Turbo spin echo (TSE) and Half Fourier acquisition turbo spin echo
(HASTE).

Table 1.4 - Pulse sequence timing parameters and associated image contrasts

Long TR

Long TE

Short TE

T2 Weighted

Proton Density
Weighted

Short TR

Not Used

T1 Weighted
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1.2.3.2

Gradient Echo Sequences

Gradient echo (GE) sequences use the gradients to refocus the spins after dephasing. These
sequences begin with an RF excitation pulse with a flip angle that is smaller than 90o,
allowing for faster imaging. After the excitation pulse, a negative gradient is applied to bring
individual spins back into phase. This technique does not account for dephasing due to field
inhomogeneities, making these sequences sensitive to T2* effects. Figure 1.7 shows the
timing diagram for a simple GE sequence.

Figure 1.7 - Timing diagram for basic gradient echo sequence. Adapted from reference
75.

The contrast in GE sequences is dependent on the flip angle of the RF pulse, TR and TE. In
basic GE sequences, the TR time is relatively long (500 ms) while in basic fast GE
sequences, the TR time is very short (100 – 150 ms).75 TR times in GE sequences are much
shorter than those in SE sequences because the smaller flip angles used in GE allows for part
of the longitudinal magnetization to remain intact, shortening the time required to return to
equilibrium. 75 Table 1.5 shows how the flip angle and TE can be varied to achieve different
contrasts with basic GE sequences.
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Table 1.5 - TE and flip angle for achieving different contrasts with basic GE
sequences75,79
Short TE (<10 ms)

Long TE (25 – 30 ms)

Small Flip Angle

Proton Density

T2* Weighted

(15o – 20o)

Weighted

Intermediate Flip Angle

T1 Weighted

(40o – 50o)
Large Flip Angle

Strong T1

(>80o)

Weighted

In fast GE sequences, the TR is less than the T2 time, causing the relationship between image
contrast and imaging parameters to become more complex.79 Most imaging in the clinical
setting uses the fast GE sequences, since the longer TR times lead to increased acquisition
times.79 Some commonly used GE sequences are: Fast low-angle shot (FLASH) which
produces T1 weighted contrast and balanced steady state free precession (bSSFP) which
produces T2/T1 weighted contrast.79,80
Work in the following chapters has primarily used the bSSFP pulse sequence to acquire
images. The following section describes this sequence and its usual applications.

1.2.3.3

balanced Steady State Free Precession (bSSFP)

The balanced steady state free precession (bSSFP) sequence is similar to other fast GE
sequences, except in bSSFP the application of the gradients are balanced. All applications of
each gradient in the positive direction are balanced with application in the opposite direction,
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causing the net gradient area to be zero.79–81 This leads to the refocusing of the magnetization
before the next RF pulse, conserving as much signal as possible and generating a high signal
to noise ratio.79 However, this technique is very sensitive to field inhomogeneities since these
cause dephasing of the magnetization leading to a decrease in signal.80 The timing diagram
for this pulse sequence is shown in Figure 1.8.

Figure 1.8 - Pulse sequence diagram of bSSFP pulse sequence. The net gradient area for
each applied gradient is zero. Adapted from reference 80.

The on-resonance signal intensity in bSSFP is given by the following equation, assuming that
TR << T1 and T2:80
!!! = !! !

sin !
!1
1 + cos ! + (1 − cos !)! !2

22

23

The optimal flip angle for achieving the greatest signal intensity possible is given by the
following equation and is dependent on the T1 and T2 of the tissue:80
!1
−1
cos ! = ! !2
!1
!2 + 1
At the optimal flip angle, the on-resonance signal intensity simplifies to:80
1
!2
!!! = !!
2
!1
When T1 and T2 values for a tissue are similar, for example: fat and fluids, the signal
intensity approaches half of the initial magnetization. These contrast characteristics and the
speed at which this pulse sequence can be run make it ideal for cardiac and vascular
imaging.79,80 bSSFP is also used in body imaging in oncology due to it’s increased SNR and
lower susceptibility to motion artifacts.82 bSSFP has also recently been used in fMRI, but not
to a great extent.81

1.2.4

Principles of Cellular MRI

Cellular MRI utilizes high resolution MRI and cell labeling to study the fate of cells in vivo.
In most studies cells are labeled with iron oxide nanoparticles. Intracellular iron results in
shortening of the T2 relaxation time locally,83 causing a region of signal loss, typically much
larger than the actual area occupied by the nanoparticles. This occurs because the large
magnetic susceptibility of these agents produce a large local change in the magnetic field
inhomogeneity, which changes the magnitude of the local field enough that the Larmor
frequency of the protons within the vicinity is altered. This change in Larmor frequency
causes dephasing of protons and prevents them contributing to the generation of MR signal.84
Iron oxide nanoparticles are usually classified by their size, as either (i) ultra small iron oxide
particles (USPIO), (ii) standard superparamagnetic iron oxide particles (SPIO) or (iii)
micron-sized iron oxide particles (MPIO).83,84 The USPIO particles are 10-20 nm in diameter
while SPIO particles are usually 50-100 nm. Particles in the MPIO category are
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approximately 1 µm in diameter.83 USPIO and SPIO particles are typically coated with a
biodegradable dextran; examples are Combidex® and Feridex®. MPIO particles, such as
Bangs Beads, consist of iron oxides coated with silica, or other polymers such as polystyrene,
or of iron oxides embedded within a polymer matrix. MPIOs contain much more iron per
particle compared to USPIO and SPIO. For example, a single 0.9 micron Bangs beads
contains approximately the same amount of iron as 4.3 x 106 USPIO or 1.5 x 106 SPIO
particles.85 Magnitsky et al. have shown that cells labeled with 45 ug Fe/mL MPIO contain
approximately twice as much iron per cell compared to cells labeled with 100 ug Fe/mL
SPIO and approximately 6 times as much iron as cells labeled with 100 ug Fe/mL USPIO.86
Because MPIO are non-biodegradable these particles have only been used for preclinical
research.
Most types of cells can be labeled with iron particles by simple co-incubation. Iron particles
are taken up by endocytosis and compartmentalized within endosomes in the cell cytoplasm.
To enhance iron uptake or to facilitate the labeling of non-endocytic cell types (ie. T cells)
transfection agents can be used; mixing transfection agents with iron particles prior to
labeling forms complexes, which shuttle the iron into the cells.84,87
To improve cell detection by MRI the goal is to have cells take up as much iron as possible
without impacting on the normal cell viability, phenotype or function. Most studies report no
detrimental effects of iron particles on the cell at the typical labeling concentrations used for
MRI. Very high levels of labeling, however, can lead to signs of toxicity including decreased
proliferation, production of free radicals and cell death.84
Most cellular MRI studies use high field strengths to achieve high-resolution imaging, but
clinical systems with specialized hardware have also been used. Each of these systems have
there own advantages and disadvantages, with high field systems allowing faster acquisitions
but at the cost of increased magnetic field inhomogeneity, while low field systems tend to be
more homogenous but also have increased acquisition times due to a lower intrinsic signal.
Currently, there are no iron agents approved for clinical use in North America. In the past
Feridex was approved for clinical use in the U.S.A and Canada and was widely used in the
MRI clinic for visualization of liver tumors. For this application Feridex was administered
intravenously (iv) and normal liver macrophages engulfed the iron particles causing normal
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tissue to appear with very low signal intensity, and therefore, abnormal liver tissue (tumors)
to appear bright. Feridex was taken off-market in 2008 for financial reasons. In Europe and
Asia, some USPIO remain approved for clinical use and are mostly administered iv to detect
inflammation in diseases such as atherosclerosis and multiple sclerosis (MS).88,89

1.2.5

Preclinical Applications of Cellular MRI

Cellular MRI has been used to track the fate of various types of cells in preclinical disease
models. Many of these studies have been focused on tracking the fate of stem cells in a range
of small animal models of injury and disease.90–97 The goal is to use in vivo longitudinal
imaging to identify the location of the cells after their transplantation and to monitor their
migration within the host tissue, or to other sites.
Some examples of stem cell tracking have included the tracking of stem cells after their
intracardiac transplantation in rat and pig models of myocardial infarction,94,95 the survival
and migration of mulitpotent stromal cells and embryonic stem cells in spinal cord injury
models, as well as the engraftment and migration of neural stem cells in animal models of
stroke and multiple sclerosis.91,93,96,97
Cellular MRI has also been used to monitor the survival of transplanted pancreatic islets.
Herynek et al. used a dual contrast approach to monitor SPIO labeled islet transplanted into
the liver of rats.98 Jung et al. have used heparin conjugated SPIO to labeled islets prior to
transplantation and monitored the grafts for 30 days in nude mice.99 Isogenic and allogenic
islets have also been imaged after transplantation into the live of mice, where function of the
grafts was monitored by measuring blood glycemia100 and more recently by using automated
detection on MRI.101 Work by Medarova et al. have demonstrated the feasibility of tracking
Feridex labeled islets in baboons, showing safety and long term function of the islets.102
Monitoring immune cells is another growing application of cellular MRI. Baeten et al. have
tracked the migration of myelin reactive, SPIO labeled T cells injected intravenously in both
naïve and EAE induced rats, finding differences in the cells’ migration patterns between the
groups.103 Ahrens et al. have demonstrated that dendritic cells can be effectively labeled with
anti-CD11c SPIO in vitro and that these cells could be detected in vivo following
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transplantation into quadriceps of mice.104 Dekaban et al. and Zhang et al. were able to
monitor and to quantify both mouse and human dendritic cell migration to lymph nodes in
mice after injection into the hind footpad.105,106 Work by Baumjohann et al. has tracked the
migration of dendritic cells to lymph nodes after injection into the hind footpad, both
correlating MRI signal loss with cell number and showing migration of labeled dendritic
cells into T cell rich areas of lymph nodes.107 Joo et al. have examined the effect of
prostaglandin E2 on the migration of SPIO labeled mouse dendritic cells in vivo,
demonstrating increased migration in prostaglandin treated groups.108 Ferguson et al. have
monitored the effectiveness of immunotherapy with SPIO labeled dendritic cells in a mouse
model of thymoma.109 They showed that dendritic cells primed with an antigen expressed on
the thymoma cells produced greater tumor free survival rates than compared to naïve cells
and cell primed with a different antigen.109
One of the limitations of cell tracking with iron oxide nanoparticles is the challenge of
quantifying cell number. In vitro studies have demonstrated that the amount of signal loss
that is generated from iron oxide nanoparticles, or the R2 value, is dependent on the
concentration of iron within a voxel as well as the voxel volume, pulse sequence and the field
strength used for imaging.84,110,111 The relationship between iron concentration and signal
loss is linear (within a range of low iron concentrations), but this relationship changes when
the image resolution is increased.110,112 Increasing the field strength will also increase the
sensitivity to iron, allowing for lower iron concentrations to be detected. Quantification of
the number of cells in a voxel in vivo using R2 values is more challenging. These values will
be dependent on the tissue and can change over time if cells are monitored in longitudinal
studies.112
Another limitation of cell tracking with iron and MRI is that the iron label will be diluted in
proliferating cells. Eventually, the iron content of the cells will fall below the detection limit
with MRI. Because of this relatively few studies have used cellular MRI techniques to track
cancer cells.31,47,52,69,86,113,114 However, we and others have shown that the retention of iron
particles in nonproliferative, or slowly cycling, cancer cells can be exploited to detect
particular cancer cell populations. Heyn et al. were the first to demonstrate that
nonproliferative cancer cells could be tracked by virtue of their retention of iron particles. In
this study metastatic breast cancer cells were iron-labeled and injected into the left ventricle
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of the heart for delivery to the brain. Once arrested they appeared as discrete signal voids by
MRI. Over time most of these voids disappeared as they died and were cleared, a small
percentage of the voids developed into brain metastases and a small percentage of the voids
remained for one month, throughout the experiment.47 Townson et al. injected iron-labeled
metastatic melanoma cells into the mouse liver and used MRI to show that cytotoxic
chemotherapy with doxorubicin reduced liver tumor burden but did not affect the number of
nonproliferative cancer cells.52
Magnitsky et al., showed that USPIO, SPIO and MPIO could be used to track slowly-cycling
cells in human melanoma tumors gown subcutaneously in mice for up to 6 weeks.86
Gazdzinski et al. were able to map the distribution of MPIO-labeled cancer cells in a mouse
glioma models as tumors developed over time and found that iron-retaining cells were
distributed differently in different tumor types with retention of the label in the center of the
tumor being a feature of the more invasive tumors.69 Wu et al. have examined the retention of
SPIO particles in human pancreatic cancer xenografts in nude mice for up to 3 weeks while
comparing a variety of pulse sequences, and also demonstrated retention of iron labeled cells
in the center of tumors.113
Other work has shown that iron-labeled cancer cells can be visualized within the lymph
nodes of mice.31,114,115 Foster et al. demonstrated that as few as 1,000 MPIO labeled B16F10
cells could be detected in the inguinal lymph node after direct intranodal injection.115 Kosaka
et al. have shown that breast cancer cells that were labeled with SPIO and quantum dots and
then injected in the foot pad of mice can be detected migrating to the draining lymph nodes
with both MRI and optical imaging.114 Liu et al. have also been able to visualize SPIO
labeled colon carcinoma cells injected into the foot pad migrating to the draining lymph
nodes.31

1.2.6

Clinical Applications of Cellular MRI

At present, there have been only a few clinical trials that have utilized iron oxide
nanoparticles and MRI in patients. Importantly, all of these trials have been conducted
outside of North America because of the lack of agents approved for patients. 116,117
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Several of these studies have focused on tracking the fate of transplanted stem cells. For
example, Zhu et al. (China) implanted Feridex labeled neural stem cells directly into the
brain in patients with traumatic brain injury and demonstrated engraftment and migration to
the site of injury.118 Callera and De Mello (Brazil) labeled autologous bone marrow derived
CD34+ cells with magnetic beads targeted to CD34 and implanted these cells directly into
the spinal cord of patients with spinal cord injury, observing migration of the cells from the
injection site to the injury.119 The transplantation of Feridex labeled mesenchymal stem cells
in amyotrophic lateral sclerosis (ALS) and MS has also been monitored using MRI by
Karussis et al (Israel).120
There is also interest in the utility of cellular MRI for monitoring the fate of pancreatic islets
transplanted for treating diabetes. Saudek et al. (Czech Republic) were the first to
demonstrate that Resovist-labeled islets could be safely labeled and that their survival in the
liver could be monitored in type I diabetes patients.121 Toso et al. performed a similar study
(Switzerland) where pancreatic islets were labeled with SPIO particles prior to
transplantation into patient livers and have shown a therapeutic effect for up to 2 years in one
patient.122
Cellular MRI has also been used in immunotherapy studies to track SPIO-labeled dendritic
cells after intranodal injection in melanoma patients (Netherlands).123 One of the major
findings of this study was that the rate of successful injections was lower than expected, at
approximately 40%, which was unknown prior to this study.123 This study demonstrated the
utility of cellular MRI in determining if the initial transplantation and delivery of cells was
successful.
The USPIO, ferumoxytol (Feraheme®), has recently been used for human MRI studies. This
particle is approved for use as an intravenous iron supplement in patients with iron deficiency
anemia and chronic kidney disease.124 Current research has shown that this particle can be
used for angiography as well as cell tracking.125–127 A clinical trial investigating the use of
ferumoxytol for the detection of lymph node metastases for pre-operative staging is currently
ongoing with completion expected in October 2013 (clinicaltrial.gov identifier:
NCT00920023).
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1.3

Goal and Objectives

The overall goal of this thesis was to use MRI to study the development of tumors in models
of breast cancer with an emphasis on the detection of metastasis to lymph nodes. To
accomplish this we had three main objectives:
1. To assess the normal MRI appearance and volume of the lymph nodes and spleen in
immune-compromised mouse strains typically used in cancer research.
2. To use longitudinal MRI to characterize tumor growth and metastasis in four different
murine models of breast cancer.
3. To use the concept of iron-label retention in cells to detect and track the
subpopulation of slowly-cycling (or nonproliferative) cancer cells within mammary
fat pad tumors and the lymph nodes in a mouse model of metastatic breast cancer.
The work described in Chapter 2 examines the normal MRI appearance and the volume of
the lymph nodes and spleen in three different immune-compromised mouse strains, and
investigates how exposure outside the pathogen free housing and repeated imaging sessions
affect these. The work presented in this chapter has been published in PLoS One 2011; 6(11):
e27508.
In Chapter 3 we used high resolution MRI to study cancer progression in four different
orthotopic breast cancer models, which consisted of two immune compromised mouse strains
implanted with two different human breast cancer cell lines. MRI was used to measure the
volume of primary tumors and the frequency of metastases to draining lymph nodes from the
implanted tumor. We compared MRI with traditional histology based methods for analysis.
In Chapter 4 we used cellular MRI to examine the behavior of MPIO retaining cancer cells in
vivo and evaluated the usefulness of cellular MRI for tracking non-proliferative cancer cells.
We monitored the evolution of signal loss over time in the primary tumor as well as observed
migration of the label retaining cells to draining lymph nodes. This work has been published
in Translational Oncology 2013; 6(3): 347-354.
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Chapter 2

2

Comparison of Lymph Nodes and Spleen in Immune
Compromised and Wild-Type Mice∗
2.1

Introduction

Immuno-deficient mice are routinely used in research. These mice have a limited capacity
for rejecting foreign tissue, which makes them excellent recipients for xenografts of human
cells and tissues.1 A variety of genetic mutations are known that impair immune function in
mice. Genetic loci affecting immune responses include nu (nude), SCID (severe combined
immunodeficiency), beige, and xid (X-linked immunodeficiency).2 The various mouse
mutants have differing immunological properties.

The extent to which some of these

mutations interfere with immune function can also vary with the genetic background.
Some commonly used strains of immuno-deficient mice include the nude mouse, the severe
combined immune deficiency (SCID) mouse and the NOD/SCID mouse (non-obese
diabetic/SCID). The murine recessive nude mutation on chromosome 11 arose
spontaneously.2 Homozygotes (nu/nu) are hairless from birth and completely lack a thymus
due to a failure of development of the thymic cells at the embryonic stage.2,3 The lack of the
thymus leads to many defects of the immune system, including a greatly reduced population
of T lymphocytes.
The murine recessive SCID mutation on chromosome 16 arose in the CB-17 inbred strain
(BALB/c.C57BL/Ka-Igh-1b). Homozygotes lack both B and T cells but have normal
numbers of natural killer (NK) cells, the main effectors of non-MHC restricted immunity.2 In
1995, Shultz et al. described a new immuno-deficient mouse model, the NOD/SCID,
obtained by crossing the SCID and NOD mouse strains.4 The NOD strain is characterized by
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functional deficits in NK cells, an absence of circulating complement and defects in the
differentiation and function of antigen-presenting cells.5 The NOD/SCID model combines
multiple functional defects of adaptive and innate immunity. They are very suitable for
xenografts of human cell lines.
The NOD/SCID IL2Rγ null (NOG) mouse is a relatively new immuno-deficient mouse
established in an attempt to generate a more appropriate recipient for xenotransplantation.
NOG mice are NOD/SCID mice that have an additional mutation in the common gamma
chain of the IL2 receptor (IL2Rγ).6 In addition to lacking functional T and B lymphocytes,
the IL2Rγ deficiency blocks the development of NK cells. The NOG mice have no
‘leakiness’ with age, meaning that NK cells are not ever produced. The NOG mouse accepts
heterologous cells much more easily compared with any other type of immuno-deficient
mouse. Thus, the NOG mouse is currently viewed as the most sensitive mouse model to
allow human cells to engraft, proliferate, and/or differentiate.7
The nude mouse has been widely studied in cancer research.8,9 Xenografts of many different
established human cancer cell lines have been successfully grown in nude mice after their
implantation in subcutaneous or orthotopic sites.10,11 However, the engraftment and growth
rates, and the incidence of metastases, are often enhanced in the other more immunodeficient mouse strains.1,2,12–14 A comparative study of tumor growth in various cancer cell
lines in different mouse strains (nude, C.B.-17 SCID (SCID) and NOD/SCID mice) has
shown a better growth rate in the NOD/SCID mouse.1 Taghian et al. compared the
transplantability of six human cancer cell lines in nude and SCID mice. For 6/6 cell lines,
the number of cells required to establish a tumor was significantly lower for SCID mice
compared to nude mice.15 Xie et al. showed that nude and SCID mice were equally suitable
for growing three different human cancer cell lines (bladder, breast and melanoma), but that
the metastatic capacity of the cells was much better expressed in the SCID mice.14
Magnetic resonance imaging (MRI) is becoming increasingly common as a tool for the
noninvasive monitoring of disease in a wide range of murine models. Therefore, it is
important to understand the baseline MRI appearance of the lymph nodes and spleen in
experimental mice. Three strains of immune-compromised mice were chosen (nude, SCID
and NOG) because of their frequent use as experimental models in research. Because of the
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altered structure and function in the lymphoid organs (spleen, lymph nodes) in immunodeficient mice we hypothesized that there would be noteworthy differences in the normal
MRI appearance of the lymph nodes and spleen in immuno-deficient mice compared to
immuno-competent mice. In the current study we use MRI to characterize the lymph nodes
and spleen in three different immuno-deficient mice (nude, SCID and NOG) and the
immune-competent mouse strain C57Bl/6.

2.2

Materials and Methods

All animal experiments were approved by the Animal Use Subcommittee of the University
Council on Animal Care at The University of Western Ontario following the guidelines of
the Canadian Council on Animal Care (protocol # 2010-210).

2.2.1

Mice

Mice used included the wild-type C57Bl/6J mice (Jackson Laboratories, age 7 to 9 weeks at
arrival) and immuno-deficient nude (nu/nu) mice (Charles River Canada, age 6 to 8 weeks at
arrival), CB-17 SCID (CB17/Icr-Prkdcscid/IcrIcoCrl) mice (Charles River Canada, age 6 to 8
weeks at arrival) and NOG mice (Jackson Laboratories, age 8 to 11 weeks at arrival). In the
first experiment 4 mice per strain were imaged once, within a week of arrival, to compare the
MRI appearance of the lymphoid organs.

In the second experiment 4 mice per strain

(excluding the NOG mice, which the first experiment revealed had no MR visible nodes)
were imaged on days 7, 14 and 28 after arrival to assess changes in the appearance of the
nodes and spleens over time. The immuno-deficient mice used in this longitudinal imaging
experiment left the barrier proper for the first scanning session and returned to an external
barrier where they were housed in safe conditions within ventilated cages for the reminder of
the study. All animals were sacrificed after the final imaging time point and the tissues of
interest were weighed and prepared for histology.
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2.2.2

Magnetic Resonance Imaging

All imaging was performed on a 1.5T CV/I MRI scanner (General Electric Medical Systems,
Milwaukee, WI) using a custom built gradient coil insert (inner diameter = 17.5cm,
maximum gradient strength = 500 mT/m, and peak slew rate = 3000 T/m/sec) and a custom
built solenoid mouse body radio-frequency (RF) coil (4cm in length and 3cm in diameter).
All mice were imaged with a 3D balanced steady state free precession (bSSFP) pulse
sequence. The bSSFP sequence was chosen because it provides very high SNR efficiency,
allowing for high resolution image acquisitions of the whole mouse body in reasonable scan
times, and because it produces very good soft tissue contrast, related to T2/T1. The scan
parameters for bSSFP were as follows: repetition time = 6.7 ms, echo time = 3.3 ms, flip
angle = 40o, bandwidth = +/- 31.25 kHz, matrix =300x300, field of view (FOV) = 6 cm, 0.2
mm slice thickness, 200 µm isotropic spatial resolution, 4 signal averages (NEX), 4 RF phase
cycles and scan time of 34 minutes.
Since both fat and fluid appear with high signal intensity in bSSFP images, spin echo (SE)
images were acquired with T1- and T2-weighting in some nude mice. These additional
image contrasts helped with the interpretation of the hyperintense regions within some lymph
nodes on bSSFP images. The SE parameters were as follows: repetition time = 2000 ms for
T2w and 600ms for T1w, echo time = 80ms for T2w and 25ms for T1w, matrix = 256x256,
FOV = 6 cm FOV, in-plane spatial resolution = 234 microns, slice thickness = 500 microns,
12 NEX, scan time = ~ 15 minutes for T1w and ~ 51 minutes for T2w images.

2.2.3

Image Analysis

The volume of the spleen and the left and right axillary, brachial, inguinal and popliteal
lymph nodes were measured by manual segmentation from all of the acquired images. The
axillary, brachial, inguinal and popliteal lymph nodes were chosen for comparison since they
are easily visualized and are commonly investigated in metastasis and immunotherapy
experiments. The Osirix image analysis software16 was used to make all measurements from
images acquired in this study. Each organ of interest was segmented individually on every
image slice to create a series of regions of interest (ROI). One ROI from the organ’s ROI
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series was selected and the volume was calculated by using the ROI volume calculation tool
available within the software package. This procedure was repeated to calculate the volume
for all organs in each image. All volume data were compared statistically using Graph Pad
Prism analysis software (GraphPad Software, La Jolla, CA).

2.2.4

Histopathological Analysis

All animals were euthanized using a carbon dioxide gas chamber. Lymph nodes were then
removed and placed in 3.75 % formalin. The fixed lymph nodes were imbedded into paraffin
blocks and sectioned. Four 5-µm sections were cut from each block, followed by a 1-µm gap
and an additional four 5-µm sections. The sections were then stained with Hematoxylin and
Eosin (H&E).

2.3

2.3.1

Results

Lymph Node Appearance and Volumes

In the first set of studies, C57Bl/6, SCID, nude and NOG mice were imaged once. Figure 2.1
shows coronal views of the whole mouse body and the locations of the axillary, brachial,
inguinal and popliteal lymph nodes in bSSFP images of a C57Bl/6 mouse. The images of
lymph nodes in the C57Bl/6 mice appear with uniform signal intensity and have good
contrast with the surrounding tissue for the brachial, inguinal and popliteal lymph nodes,
which are located in fat pads.
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Figure 2.1 - (A) Whole mouse body bSSFP image of a C57Bl/6 mouse showing both the
brachial and inguinal lymph nodes (arrows) and (B) 3D reconstruction showing the
location of various lymph nodes within the mouse; 1 – axillary node, 2 – brachial node,
3 – inguinal node, 4 – popliteal node.

Representative images of these nodes in the different mouse strains are shown in Figure
2.2A. There were some notable differences in the MRI appearance of the lymph nodes in the
immune compromised mice. First, in images of some of the lymph nodes in the nude mice a
large hyperintense region was visible within the node. This was observed in the axillary (5/8
nodes), brachial (8/8 nodes) and inguinal nodes (6/8 nodes). While the brachial nodes most
frequently exhibited these hyperintense areas, these areas were anatomically the most
obvious in the axillary nodes. This pattern of hyperintensity was also present in some nodes
in SCID mice, but at a lower frequency; in the brachial (3/8 nodes), inguinal (1/8 nodes) and
popliteal (2/8 nodes) nodes. Bright spots were never observed in C57Bl/6 mice. No lymph
nodes were visible in the images of the NOG mice.
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Figure 2.2 (previous page) - MR appearance and volumes of lymph nodes various
mouse strains. (A) MR appearance of the axillary, brachial, inguinal and popliteal
lymph nodes in C57Bl/6, Nude, CB-17 SCID and NOG mice. The brachial, inguinal and
popliteal lymph nodes are easiest to visualize due to their location within a fat pad.
Lymphatic vessels are also visible in acquired images (arrowhead). Images for the
NOG mice are included for completeness although there were no MRI detectable lymph
nodes. (B) Volumes of the axillary, brachial, inguinal and popliteal lymph nodes in
C57Bl/6, Nude and CB-17 SCID mice. The brachial, inguinal and popliteal lymph nodes
in CB-17 SCID mice were found to be significantly smaller than those in both C57Bl/6
and Nude mice (*, p < 0.0001 for brachial and inguinal and p = 0.0128 for popliteal).
The axillary node in Nude mice was significantly larger than those in both CB-17 SCID
and C57Bl/6 mice (**, p < 0.0001). One way ANOVA test was used. Error bars
represent the standard deviation.

Measuring the lymph node volumes from the 3D MR images also revealed differences
between mouse strains (Figure 2.2B). The mean lymph node volumes measured from images
acquired in the first experiment are listed in Table 2.1. All volumes are listed as the mean +/standard deviation of the mean. The mean values were compared using a one way Analysis
of Variance (ANOVA) test with a Tukey multiple comparison posttest. The brachial, inguinal
and popliteal nodes in SCID mice were significantly smaller than those in both nude mice
and C57Bl/6 mice (p < 0.0001 for brachial and inguinal and p = 0.0128 for popliteal). The
axillary nodes in nude mice were significantly larger than those in C57Bl/6 mice (p <
0.0001), while the brachial, inguinal and popliteal node volumes were comparable between
these two strains. The size of all lymph nodes was most variable in the nude mouse.
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Table 2.1 - Lymph node volumes of C57Bl/6, Nude and CB-17 SCID mice. All volumes
listed as mean ± standard deviation.
Lymph Node

C57Bl/6J

Nude

CB-17 SCID

Axillary Node Volume (mm3)

2.73 ± 0.25

6.55 ± 3.35

0.54 ± 0.12

Brachial Node Volume (mm3)

3.68 ± 0.76

4.06 ± 1.47

0.53 ± 0.09

Inguinal Node Volume (mm3)

2.52 ± 0.39

2.65 ± 0.45

0.54 ± 0.21

Popliteal Node Volume (mm3)

0.78 ± 0.59

0.70 ± 0.38

0.17 ± 0.06

Examination of the H&E staining revealed clear differences in the morphology of nodes from
the different mouse strains (Figure 2.3). In the immune competent C57Bl/6 mice, the nodes
contain all the major structures including the cortex, paracortex and medulla. Areas rich in T
and B cells are present and fully formed in this strain. Lymph nodes from nude mice have a
similar structure; the B cell follicles can easily be distinguished from other structures in the
node. However, T cells are lacking in these animals, leaving vacant areas within the
paracortex. SCID mouse lymph nodes do not contain any defined structures. The cortex,
paracortex and medulla cannot easily be distinguished.
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Figure 2.3 - H&E sections of brachial lymph nodes from C57B/l6, Nude and C.B.-17
SCID mice. Whole nodes are shown at 5x magnification. The T-cell rich paracortex
(arrowsheads) and B-cell rich follicles (arrows) can be easily seen in the nodes of
C57B/l6 mice, where as in Nude mouse lymph nodes, only the B-cell rich follicles can be
seen (arrows). In the areas of the paracortex where T cells should be found, vacant
areas are detected (arrowheads), helping to explain the hyperintense appearance of
many of these nodes in MR images. Nodes in SCID mice lack both the paracortex and
follicles, leaving these nodes underdeveloped and significantly smaller in size.

In some nodes the cavities in the lymph nodes were pronounced. In Figure 2.4 an H&E
stained section of a representative axillary node from a nude mouse is shown along with the
corresponding bSSFP image that shows a large region of bright signal within the node. In the
T1w images, the central portion of the lymph node had low signal intensity while in the
corresponding T2w image the central portion of the node was hyperintense, as in the bSSFP
image (Figure 2.5). Lymph node tissue in NOG mice could not be found upon dissection.
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Figure 2.4 - MR image (bSSFP) of a nude mouse axillary node with hyperintense center
(A) with corresponding histology (B). The hyperintense area within the lymph node
(arrow) corresponds to a cavity that is visible in the histology. The section in (B) is
rotated relative to the image in (A).
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Figure 2.5 - MR images of a nude mouse brachial lymph node acquired with different
pulse sequences. (A) bSSFP image of whole mouse body, (B) bSSFP image of lymph
node, (C) T1w SE of lymph node (TR = 600 ms, TE = 25 ms), (D) T2w SE of lymph node
(TR = 2000 ms, TE = 80 ms)

2.3.2

Spleen Appearance and Volumes

Differences in the MR appearance of the spleen were also observed. The images of the spleen
in the C57Bl/6 and nude mice were similar in appearance with a heterogeneous pattern of
signal intensities giving it a mottled appearance (Figure 2.6). The images of the spleen in
SCID and NOG mice were visually different. The spleens in SCID mice had a higher signal
intensity, which was uniform throughout (Figure 2.6C). The spleens in NOG mice appeared
with very low signal intensity, appearing black (Figure 2.6D). The spleen volumes were
compared using a one way ANOVA with a Tukey multiple comparison posttest and the
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average volume of the spleen was found to be significantly smaller (p < 0.0001) in both
SCID (23.2 +/- 3.6 mm3) and NOG (15.5 +/- 1.3 mm3) mice compared to the both nude (72.9
+/- 1.4 mm3) and C57Bl/6 (71.1 +/- 1.6 mm3) strains (Figure 2.6E).

Figure 2.6 - bSSFP images of the spleen in (A) C57Bl/6, (B) nude, (C) CB-17 SCID and
(D) NOG. (E) Spleen volume in C57Bl/6, Nude, CB-17 SCID and NOG mice. (*) Spleen
volumes were significantly smaller in CB-17 SCID and NOG mice (p < 0.0001)
compared to C57Bl/6 and nude mice. One way ANOVA test was used. Error bars
represent the standard deviation.

2.3.3

Changes in Lymph Node Volumes Over Time

We next wanted to determine whether there were changes in the MR appearance of lymph
nodes over time. C57Bl/6, nude and SCID mice were imaged on days 7, 14 and 28 after
arrival. The lymph node volumes were measured from images acquired at each time point
(Figure 2.7). The lymph node volumes were compared over time using a repeated measures
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ANOVA test with a Tukey multiple comparison posttest. In all mice there were changes in
the lymph node volumes over time. In the C57Bl/6 mice the inguinal node decreased in
volume significantly between day 7 and day 28 (p = 0.0071) (Figure 2.7A). In nude mice
the axillary, inguinal and popliteal nodes increased in volume over time; the axillary (p =
0.010) and inguinal nodes (p = 0.016) were significantly larger at day 28 compared to day 7
and the popliteal node was significantly larger at day 14 compared to day 7 (p = 0.0046)
(Figure 2.7B). In SCID mice, the volumes of the brachial and inguinal nodes decreased
significantly over time. The brachial (p = 0.013) and inguinal nodes (p = 0.023) were
significantly smaller at day 14 compared to day 7. There were no significant differences in
the volumes of the axillary and popliteal lymph nodes over time (Figure 2.7C).
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Figure 2.7 - Lymph node volumes over time. (A) C57Bl/6 mice. (B) Nude mice. (C) CB17 SCID mice. Significant differences were found in the inguinal (p = 0.0071) nodes of
C57Bl/6 mice. Significant differences were also found in the axillary (p = 0.0104),
inguinal (p = 0.0155) and popliteal (p = 0.0046) nodes of nude mice. Significant
differences were also found in SCID mice in the brachial (p = 0.0130) and inguinal
nodes (p = 0.0225). (*) Significantly different compared to day 7. Repeated measures
ANOVA test was used. Error bars represent the standard deviation.
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2.4

Discussion

This is the first study to use MRI to assess the appearance of the lymph nodes and spleen in
various immuno-deficient and wild-type mouse strains. Given the substantial differences in
the cellular composition of the immune systems in these mice, and reports from a small
number of pathological studies which noted differences in lymph node morphology between
different mouse strains, we hypothesized that the MRI appearance of the lymphoid tissues
would also be disparate in the immuno-deficient and wild-type mouse strains we examined.
MRI revealed some considerable differences in the appearance of lymph nodes in the
different mice. Most notably, some lymph nodes in nude and SCID mice appeared with a
region of signal hyperintensity in bSSFP images. By comparing the bSSFP images with T1and T2-weighted SE images we were able to determine that the high signal intensity in the
bSSFP images is most likely due to the presence of fluid within the node. Fluids have long
T1 and T2 relaxation times. In T1-weighted images tissues with long T1 relaxation times
appear dark, while in T2-weighted images tissues with long T2 relaxation times appear
bright. Contrast in bSSFP images is related to T2/T1 and tissues with similar T1 and T2
values, like fluids (and fat), will have T2/T1 close to 1, which results in high signal intensity.
It is also worth noting that when nude mice were followed over time with MRI, those nodes
that appeared with a region of signal hyperintensity did not change in appearance during the
imaging experiment.
There are relatively few papers that describe the anatomical or cellular features of normal
lymph nodes in immune-deficient mice. In a paper by Sainte-Marie and Peng,17 8 types of
lymph nodes, in 7 nude and 4 C57Bl/10 mice, were carefully assessed by histopathology.
They showed that in nude mice the absence of the thymus greatly inhibits the development of
the lymphocyte population in the cortex, creating a small cavity. In addition, in some mice a
cyst of variable size was found in the axillary or brachial nodes, often near the hilus.17 These
findings are similar to our observations in nude mice by MRI, where fluid filled cavities were
observed in the axillary, brachial and inguinal nodes.
A histological examination of the immune organs in SCID mice, by Ge et al., showed that the
lymph nodes had no clear cortex and appeared to be totally devoid of lymphocytes.18 These
modifications of lymph node anatomy could also be expected to result in features such as
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cavities or cysts. Our histology demonstrated that nodes which appeared with a region of
high signal intensity in MR images, had a cavity within them, supporting the notion of a
fluid-filled node.
Exposure of immuno-deficient mice to potentially pathogenic organisms must be restricted.
Specific pathogen free (SPF) housing systems, often referred to as barrier facilities, are
commonly used to house immuno-deficient mice and employ sterilization of feed, bedding,
water, and cages along with the use of filter-top or individually ventilated caging systems and
strict adherence to aseptic techniques for animal handling. Lymph nodes may enlarge when
immune cells react to pathogen, such as virus or bacteria, due to proliferation of
lymphocytes. Swollen glands, common to many illnesses, are an example of nodes enlarging
in response to a pathogen. The immuno-deficient mice used in our longitudinal imaging
studies leave the barrier facility for the first scanning session (day 7 after arrival) and
thereafter were housed within an external barrier in ventilated cages. They were transported
to/from the external barrier and the MRI facility for the next two scans (days 14 and 28). We
hypothesized that the transfer between barriers and time spent outside of the barrier in the
MRI facility, would result in changes in the size of the lymph nodes. To test this we imaged
wild-type, nude and SCID mice at three time-points and measured the lymph node volumes.
Changes in the lymph node volumes were measured for all mice. The largest changes were
observed in the nude mice, however, the node volume in nude mice was found to be the most
variable for all scans. In SCID mice the node volume was actually observed to decrease over
time. However, there was no trend for increasing node size with number of times imaged (or
number of transfers out of the barrier).
Even though the lymph nodes in these immuno-deficient mice are underdeveloped, or
rudimentary, many studies show that the lymph nodes are a frequent site of cancer
metastases.11,19,20 In fact several studies suggest that lymph node metastases are more
common in the mice with the more severe immunodeficiencies.12,13 Dewan et al. have
reported that the rate of metastasis of human breast cancer cells (MDA-MB-231) is much
higher in NOG mice, compared to NOD/SCID mice inoculated in the same way.12 This
included metastasis to the regional lymph nodes. It is interesting that, even though lymph
nodes in NOG mice are not obvious at dissection, and not visible in MR images, the
rudimentary node tissue still provides a suitable microenvironment for metastatic growth.
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When lymph nodes are abnormal they increase in size.21 Enlarged lymph nodes are readily
visible in MRI. In fact, traditionally, MRI of the lymphatic system has been focused on
conventional anatomical imaging whereby enlargement of lymph nodes is considered the
primary diagnostic criterion for disease. Secondary architectural and pathological changes
are also often apparent on MRI. It is therefore important to recognize that, in the different
mouse strains we imaged, the size and appearance of the lymph nodes is quite variable in
healthy animals and the lymph node volumes change over time in both wildtype and
immuno-deficient mouse strains. A change in the lymph node size, as measured by MRI, in
these mice should not be considered evidence of disease without additional validation.
In diseased lymph nodes the tissue is sometimes homogenized so that the cortical and
medullary areas are no longer differentiated.22 Necrosis may lead to accumulation of fluid
(pus) within nodes, and can cause a fluid filed cavity. It is therefore very important to
recognize that some diseased nodes can appear hyperintense in bSSFP and T2-weighted
images (or with low signal in a T1-weighted image) and that this has the potential to be
confused with normal lymph nodes in non-tumor bearing immuno-deficient mice.
The MRI appearance of the spleen in the different mouse strains was also notable. The
spleens of wild-type and nude mice were quite similar in size and MRI appearance; a distinct
architectural pattern is observed in MR images of the spleen in wild-type and nude mice. In
SCID and NOG mice, the images show a smaller spleen (3-5x smaller in volume) devoid of
pattern and in the case of the NOG mouse acellular.

These differences in the MRI

appearance likely reflect the impaired development of the spleen in these mice.
The normal spleen is composed of what is known as (non-lymphoid) red pulp and (lymphoid)
white pulp.

Red pulp consists of connective tissue and many splenic sinuses that are

engorged with blood, giving it a red appearance. It functions to filter the blood and is a
storage site for red blood cells.23 It is also a reserve site for monocytes, which upon injury or
disease leave the spleen and migrate to tissues for repair.23 The high blood content causes it
to appear with very low signal intensity in bSSFP images. White pulp consists of lymph
nodules (germinal centers), composed of follicles, and periarteriolar lymphoid sheaths.
White pulp is rich in lymphocytes.23
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SCID mice contain a defect preventing the functional development of T- and Blymphocytes.24,25 Ge et al. have shown by histology that SCID mice have relatively empty
splenic follicles.18 It is because of these deficits the spleen in SCID mice is rudimentary in
appearance and function. By MRI it appears to have no tissue contrast within it, suggesting
minimal structural features.

The NOG mouse is a SCID mouse strain that has multi-

functional defects in NK activity, macrophage function, complement activity and dendritic
cell function, in addition to lacking T- and B-cells. In all NOG mice examined by MRI the
spleen appeared black reflecting an absence of signal likely due to an absence of cellularity.
In summary, this paper investigates an important technical aspect of mouse body imaging,
namely the differential appearance of lymph nodes and spleens in 4 commonly used strains
of experimental mice (C57Bl/6, nu/nu, CB-17 SCID, and NOG). These strains of mice are
widely used for cancer research, and imaging is often used to identify metastasis to lymph
nodes and distant organs. The use of these mice is not standardized; different laboratories use
certain mice for a variety of reasons, and differences in the appearance of the lymph nodes
across the strains can be a source of confusion in data interpretation. We have shown that
there are particular features within the nodes of some mice that can mimic the appearance of
pathology. We have found that changes in the size of nodes, in healthy mice, that occur with
repeated imaging fall within the typical range of node sizes, which show variability. By
presenting knowledge of the normal MRI appearance of the lymphoid organs in healthy,
immuno-deficient and immuno-competent mice we provide information that will help to
avoid data misinterpretation and to advance the field.
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Chapter 3

3

Comparing Tumor Growth and Metastasis in Xenograft
Models of Breast Cancer using MRI
3.1

Introduction

Metastasis from a primary tumor is the main cause of most cancer related deaths.1,2 A
common method for studying metastasis and tumor progression involves conducting
histology-based studies, which use tissue samples collected at multiple timepoints and
require large groups of animals. These studies only provide a snapshot of how a particular
tumor is progressing over time. These studies also do not allow for the occurrence of specific
events, such as metastases, to be studied in detail to determine their time course of
development.
With the development of powerful preclinical imaging technologies, such as high resolution
MRI, many of the issues with the current methods for studying tumor metastases, such as
only being able to examine portion of an organ and potentially missing metastatic foci for
analysis, can be avoided.3 High resolution MRI allows for whole mouse body imaging. This
gives more information about the progression of the tumor and where additional metastatic
disease may be located. Imaging also allows the same animals to be monitored over time,
allowing the sequence of events from tumor development to the formation of obvious
metastases to be determined for each animal. These longitudinal studies require fewer
animals compared to traditional histological studies.
A wide variety of models are currently used to study cancer metastases.4 Some of these
models consist of transgenic animals that will spontaneously form tumors while others are
transplant models that use either syngenic, allogenic or xenogenic grafts of cancer cells.2,4
Xenogenic models are frequently used since these models allow human cancers to be studied
in vivo, but require animals with significant immune deficiencies for proper engraftment.
These immune deficient models pose a different problem, as the immune system is known to
play a role in the development of tumors, potentially altering their growth characteristics and
metastases.2
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Hudson et al. examined the effect of these mutations on tumor growth and formation and
found that animals with more pronounced immune deficiencies produced larger tumors and
had a slightly higher percentage of tumors form.5
Carreno et al. observed similar results when comparing the ability of human melanoma cells
derived from cell lines to form metastases in the lungs of SCID, NOD/SCID, NOD/SCID
B2null and NOD/SCID IL2Rnull mice when injected intravenously.6 The ability of MDAMB-435 breast cancer cells implanted into the mammary fat pad of nude, SCID and NIH-3
mice to metastasize to the lung has been studied by Price et al. who found the highest
incidence of metastases and the most metastatic foci in the lungs of SCID mice.7 In the same
study, they also demonstrated a difference in tumorigenicity in different breast cancer cell
lines and how the tumorigenicity can be affected by implanting cells under different
conditions, such as with matrigel, fibroblasts and even normal breast epithelial cells.7
Xie et al. compared the formation of spontaneous lung metastases from various cancer cell
lines in nude and SCID strains. They found that more metastases formed in SCID mice
compared to nude mice in most of the cell lines that were examined and that the MDA-MB435 cell line formed the highest number of metastases in both of the strains examined.8
Although many investigators have studied the effect of the various immune deficiency
mutations on tumor growth and spontaneous metastases to the lungs and other major organs,
there is little data available on the effects of immune deficiency on the development of
metastases in regional lymph nodes. The lymph nodes are very small in some immunecompromised mouse strains; for example most nodes in NOD/SCID IL2Rnull mice are
absent or rudimentary and difficult to locate by dissection or high resolution MRI.9
In this study, our goal was to compare tumor formation and lymph node metastasis in nude
and SCID mice using high resolution MRI. We compared MRI to basic histology to evaluate
the utility of MRI for monitoring the development of the primary tumor and quantifying
metastases.
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3.2
3.2.1

Materials and methods
Animal Models

Female nude (nu/nu) and C.B.-17 SCID mice (CB17/Icr-Prkdcscid/IcrIcoCrl), 6 to 8 weeks
old, were injected into the thoracic mammary fat pad with 1 x 106 MDA-MB-231 or MDAMB-435 cells, resulting in a total of four groups (n = 8 per group). The MDA-MB-435 cell
line has recently been reclassified as a melanoma from a ductal carcinoma. More information
about this cell line is provided in the discussion.
For the cell injection, the animals were anesthetized using isofluorane (3% for induction
and1% for maintenance) in oxygen and an incision was made between the centre of the chest
and the right forelimb, just below shoulder level and the mammary fat pad was exposed.
Cells suspended in HBSS were injected into the fat pad in a volume of 50 µL. The incision
was then closed with Vet Bond surgical glue (3M, London, Ontario, Canada) and the mouse
was weighed and allowed to recover.

3.2.2

MRI imaging in mice

All mice received two MRI scans one week apart. The first MRI scan was conducted when
the tumor diameter had reached approximately 1 to 1.5 cm. Mice that had received 231 cells
were scanned on days 21 and 28 while mice that received 435 cells were scanned on days 30
and 37; since the growth rates of the two cell lines was known to be different (slower for
435).
All imaging was performed on a 1.5 T GE Scanner using custom-built hardware, including a
gradient insert coil and mouse body radiofrequency coil. A 3D balanced steady state free
precession (bSSFP) pulse sequence was used to acquire full body images of each animal. The
imaging parameters were a flip angle of 40º, a receiver bandwidth of 31.25 kHz, a TR of 6.7
ms, a TE of 3.3 ms, 4 phase cycles, 4 averages, half phase field of view and 200-micrometer
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isotropic resolution. Animals were anesthetized during imaging using the same procedures as
those used for performing the mammary fat pad injections.

3.2.3

Histology

Mice were sacrificed following their final scan and the primary tumor, left and right axillary
and brachial lymph nodes were removed. Tissues were fixed in formalin and embedded in
paraffin for sectioning. Five µm thick tissue sections were cut and stained with Hemotoxilyn
and Eosin (H&E).

3.2.4

Image Analysis
The Osirix image analysis software10 was used to make all measurements from

images acquired in this study. The volume of the primary tumor and of the left and right
axillary and brachial lymph nodes were measured by manual segmentation from all of the
acquired images. Each tumor or lymph node of interest was segmented individually on every
image slice to create a series of regions of interest (ROI). One ROI from the organ’s ROI
series was selected and the volume was calculated by using the ROI volume calculation tool
available within the software package. This procedure was repeated to calculate the volume
for all organs of interest in each image.

3.2.5

Statistical Analysis
All volume data were compared statistically using Graph Pad Prism analysis software

(GraphPad Software, La Jolla, CA). Tumor volumes were compared using a two-way
Analysis of Variance test. Lymph node volumes were compared using a Kruskal-Wallis test.
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A Fisher’s Exact test was used to compare the number of animals in each group that
developed metastases and to determine which factors had a significant effect.

3.3
3.3.1

Results
Differences in Tumor Growth

3.3.1.1

MRI Appearance of Primary Tumors and Histology

With the 3D MRI techniques used in this study, we were able to visualize the entire mouse
body, the primary tumor in the mammary fat pad and the lymph nodes (Figure 3.1). The
number of animals that formed tumors was similar between strains and cell lines (Table 3.1).
Tumors in all groups displayed signal heterogeneity (Figure 3.2), however this was more
pronounced in the groups that received 231 cells, which also produced larger tumors (Figure
3.2A and C). The MRI appearance of tumors from the same cell line was similar, regardless
of the strain.

Table 3.1 – Number of animals in each group that formed tumors
MBA-MB-231

MDA-MB-435

Nude

7/8

8/8

SCID

8/8

8/8
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Figure 3.1 - Image of tumor bearing mouse. (A) Whole mouse body. T - tumor, H heart, L - lungs, G - gut. (B) Image of axillary lymph node (outlined in yellow). (C)
Image of brachial lymph node (outlined in yellow).
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Figure 3.2 – Appearance of tumors at both scan time points. Tumors generated from
MDA-MB-231 cells (A - nude and C - SCID) are much larger and have regions of
heterogeneous signal intensity (arrowheads). Tumors generated from MDA-MB-435
cells (B - nude and D - SCID) are much smaller and have a more homogeneous
appearance (arrows). The MRI appearance of tumors for each cell line was similar
regardless of the strain. Scan 1 – day 21 for groups with 231 cells, day 30 for groups
with 435 cells; Scan 2 – day 28 for groups with 231 cells, day 37 for groups with 435
cells.

Tumors generated from the same cell line had a similar histological appearance, regardless of
the strain. Figure 3.3 shows H&E stained sections of tumors from all groups. Examination of
the tumors revealed that they frequently contained regions of fluid accumulation. This is
consistent with the heterogeneous appearance in MR images; signal hyperintensity in bSSFP
images represents the presence of fluid or fat accumulation. These tumors also had tracks of
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stromal cells that were not very well defined from the tumor cells. We also noticed that some
tumors had areas of decreased cellularity and areas that appeared similar to lipid vacuoles.

Figure 3.3 - H&E stained sections of tumors. (A, B) Tumor from nude mouse injected
with 231 cells. (C, D) Tumor from nude mouse injected with 435 cells. (E, F) Tumor
from SCID mouse injected with 231 cells. (G, H) Tumor from SCID mouse injected
with 435 cells. Images A, C, E, and G were taken at 10x magnification. Images B, D, F
and H were taken at 40x magnification. The box in images A, C, E and G highlights the
area that is shown in the adjacent image in the second column.
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3.3.1.2

Tumor Volume

Because all images were acquired in 3D tumor volume can be measured (Figure 3.4). At scan
1, both strain and cell line had a significant effect on the tumor volume. Tumors produced
from the 231 cell line were much larger and tumors produced in the nude strain were also
larger. At the second scan time point, the effect of the strain on tumor volume is not
significant, but the effect of the cell line is. Tumors produced from the 231 cell line were
much larger than those produced from the 435 line. The 231 tumors reached a diameter of 1
to 1.5 cm quicker than those produced from the 435 cells. Animals that bore the 231 tumors
were initially imaged on day 21 whereas animals with 435 tumors were imaged for the first
time on day 30, regardless of the strain. On average, tumors from nude mice with 231 cells
were approximately 17 and 19 times larger than those from nude mice with 435 cells at the
first and second scan time points respectively. In SCID mice with 231 cells, tumors were
approximately 24 and 29 times larger than those from SCID mice with 435 cells at the first
and second scan time points respectively.
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Figure 3.4 – Tumor volumes over time. For animals injected with MDA-MB-231 cells
(231 cells), Scan 1 was at 21 days and Scan 2 was at 28 days. For animals injected with
MDA-MB-435 cells (435 cells), Scan 1 was at 30 days and Scan 2 was at 37 days. **
Significant compared to nude mice. * Significant compared to the 231 cell line.

3.3.2

Differences in Metastases

The thoracic mammary fat pad, where cells were injected, is drained by both the axillary and
brachial lymph nodes. From our 3D MR images, we were able to determine the volume of
both these lymph nodes, as well as examine these nodes for an abnormal MRI appearance,
which may be evidence of metastatic disease, before a post mortem exam.
Image data from lymph nodes in tumor bearing mice was compared to data from healthy
control mice that are presented in Chapter 2. The data from the day 28-time point in the
longitudinal experiment in Chapter 2 was used specifically to match the number of times that
animals had been removed from pathogen free housing conditions.
All axillary and brachial lymph nodes were sectioned and examined by H&E staining for
evidence of metastasis and were compared with the image data.
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3.3.2.1

Lymph Node Appearance

Lymph nodes had a variable appearance in the MRI images at both scan time points. In nude
mice injected with 231 cells, the lymph nodes were typically enlarged and had a
heterogeneous appearance (Figure 3.5, row 2), which may be indicative of a pathological
process within the node. Differences were seen between cell lines, with very few of the nodes
in animals injected with 435 cells displaying the altered appearance that was frequently seen
in the 231 group. Lymph nodes in animals that received the 435 cells had a similar
appearance to those of non-tumor bearing control animals, which is also shown (Figure 3.5,
rows 3 (435 tumors) and rows 1 (control)). Similar results were also observed in SCID mice.
The lymph nodes of SCID mice injected with 231 cells had a similar appearance with areas
of signal heterogeneity and enlargement (Figure 3.6, row 2).
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Figure 3.5 – MR appearance of nude mouse lymph nodes. Lymph nodes (outlined in
yellow in all images) in mice injected with MDA-MB-231 cells (row 2) were enlarged
and had a heterogeneous appearance. Lymph nodes from animals injected with MDAMB-435 cells (row 3) have a similar appearance to control animals (row 1).
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Figure 3.6 – MR appearance of SCID mouse lymph nodes. Lymph nodes (outlined in
yellow in all images) in mice injected with MDA-MB-231 cells (row 2) were enlarged
and had a heterogeneous appearance. Lymph nodes from animals injected with MDAMB-435 cells (row 3) have a similar appearance to control animals (row 1).
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3.3.2.2

Lymph Node Volume and Histology

We compared the lymph node volumes using a Kruskal-Wallis test. At the first scan time
point, the volume of the brachial nodes from nude mice injected with 231 cells were
significantly larger compared to those injected with 435 cells (p = 0.0012), while no
significant difference was observed in the axillary nodes of nude mice (p = 0.0677) (Figure
3.7A). In SCID mice, the axillary nodes from animals that received 231 cells were
significantly larger than control and 435 groups (p = 0.0012), while the brachial nodes of
animals with 231 cells were significantly larger than controls (p = 0.0186).
At the second scan time point, a significant difference was observed in both the axillary and
brachial lymph nodes from both nude and SCID strains. In the nude strain, the axillary nodes
of mice with 231 cells were significantly larger than controls (p = 0.0126), the brachial nodes
of mice with 231 cells were significantly larger than those with 435 cells (p = 0.0164). In the
SCID strain, the axillary and brachial nodes of mice with 231 cells were larger than those
that received 435 cells and controls (p = 0.0001 for both nodes).
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Figure 3.7 – Lymph node volumes. (A) Scan 1, (B) Scan 2. The lymph nodes of animals
injected with 231 cells were found to be significantly larger than those in control
animals and animals injected with 435 cells. * - Significant compared to 435 cells. + Significant compared to Controls. ‡ - Significant compared to both 435 cells and
controls.

We next examined H&E stained lymph node sections for evidence of metastases. With the
assistance of a pathologist (Dr. Alan Tuck), we looked for cells under the capsule of the
lymph nodes that had large, abnormal nuclei and a high nucleus to cytoplasm ratio. We found
no lymph node metastases in mice injected with 435 cells. In groups that received 231 cells,
of the animals that were examined, we found that 6 of 7 nude mice and 4 of 5 SCID mice had
lymph node metastases. No significant difference was found between strains in the incidence
of metastases to lymph nodes, however, 2/5 SCID mice had multiple metastatic lymph nodes
(Table 3.2).

79

80

Table 3.2 – Number of Animals injected with MDA-MB-231 cells with Single or
Multiple Lesions
No Metastases

Single Lesion

Multiple Lesions

Nude

1/7

6/7

0/7

SCID

1/5

2/5

2/5

A lymph node from a 231 tumor-bearing group was considered enlarged if its volume
measured by MRI was more than 2 standard deviations from the control node volume in the
same strain. An enlarged node in MRI did not always correspond with a node that had
evidence of metastasis by histology. Table 3.3 shows the rates of true and false positives and
negatives in the groups that received 231 cells. In nude mice with 231 tumors 11/13 mice
had enlarged lymph nodes on MRI, however, 5 of these 11 mice had metastasis determined
by histology and 6 did not. There was also one node in this group that had a normal volume,
although a metastasis was detected by histological examination. In SCID mice with 231
tumors 7/7 mice had enlarged nodes on MRI and 6/7 of these had evidence of metastasis in
the node histology. There was one false positive node. In groups that received 435 cells, all
nodes in nude mice were of a normal volume and did not contain metastases, while 3/13
nodes in SCID mice were enlarged with no metastases.
The lymph nodes that were enlarged, but non-metastatic had evidence of cellular reactivity;
macrophage hyperplasia in the SCID mouse and plasma cell hyperplasia in nude mice.
Reactivity was found in metastatic nodes as well as nodes that were normal in volume
(Figure 3.8). The reactivity could reflect an immune response to the implanted tumor.
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Table 3.3– Correspondence of lymph node volume and presence of metastases. Nodes
were considered ‘enlarged’ if their volume was more than 2 standard deviations away
from the volume of the corresponding control lymph node. Positive – Metastasis
present, Negative – No metastasis.

Nude,

True

False

False

True

Total number of

Positive

Positive

Negative

Negative

nodes analyzed

231 5

6

1

1

13

231 6

1

0

0

7

cells
SCID,
cells
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Figure 3.8 – Hematoxylin and Eosin stained lymph node sections. (A, B) Nude with 231
cells, (C, D) Nude with 435 cells, (E, F) SCID with 231 cells, and (G, H) SCID with 435
cells. Sections (A, C, E, G) are taken at x10 and sections (B, D, F, H) are taken at x40
with black boxes outlining the zoomed sections in the x10 images. In the animals
injected with 231 cells, metastases can be found underneath the lymph node capsule in
both Nude mice (A, arrowhead) and SCID mice (E, arrowheads), These metastases are
shown at a greater magnification in B and F respectively (B and F, arrowheads).
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Evidence that metastatic lymph nodes are reactive is also seen in A (arrow). No
metastases were present in the lymph nodes of animals that received 435 cells, but
evidence of reactivity was seen (arrows in C, D, G and F). In the SCID mice specifically,
areas with macrophage hyperplasia were frequently found (G and H, arrows) whereas
nude mice had regions of plasma cell hyperplasia.
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3.4

Discussion

In this study, we have compared the growth and metastasis of two cell lines in two different
strains of immune-compromised mice using high resolution MRI. We observed differences in
the volume of tumors that formed and in the volume of regional lymph nodes.
The tumor volume was affected significantly by the strain used at the first scan time point,
but it was not significant at the second scan time point. This difference in volume may be due
to differing microenvironments between the strains used in this study, but this does not have
a lasting effect on the volume as the tumors continue to progress. At both scan time points,
the cell line used had a significant effect on the tumor volume. There is a clear difference in
the growth rate between these cell lines with the 231 cells producing much larger tumors in
the short period of time that was used in this study.
We also observed that the volume of draining lymph nodes in the animals that received 231
cells were significantly larger than those that received 435 cells and/or controls. These
measurements are in agreement with our histology observations, which only found
metastases in the nodes of animals with 231 tumors. When comparing the MRI volume data
directly to our histological findings for individual nodes, we found that the volume of the
node did not always indicate the presence of a metastasis. The rate of false positives from our
volume data was highest in nude mice that received 231 cells. This result is most likely a
consequence of the high variability of lymph nodes in this strain, which was observed in
chapter 2.9 The reactivity of nodes in this strain from attempting to mount an immune
response may also contribute to the increased detection of false positives, but to a lesser
extent. We frequently observed macrophage and plasma cell hyperplasia in both metastatic
and non-metastatic lymph nodes. Plasma cell hyperplasia is a common occurrence in
rodents.11 Depending on the strength of the response the hyperplasia may cause the volume of
a non-metastatic lymph node to increase enough to be classified incorrectly by MRI as a
metastatic node. These results demonstrate that high resolution MRI is more successful at
detecting changes in lymph node volumes, in animals with greater immune deficiencies and
less variability in the lymph nodes, such as the SCID strain.
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We did not observe any lymph node metastases in animals that received the 435 cells, while
metastases to regional lymph nodes were frequently seen with the 231 cells. Other studies
have compared these cell lines and have found that the 435 cell line is more aggressive,
having a higher incidence of metastasis.12 This is contrary to what we have seen in this
current study. One possible explanation may be that amount of time used for these studies
was different. In our current study, no animals were examined after 37 days or just over 5
weeks. In the study mentioned above, the animals were examined for metastases for as long
as 16 weeks post tumor implantation.12 Other studies using the 435 cell line have examined
animals for as long as 54 days8 and even 6 weeks post resection of 1.5 cm tumors.7 This
difference in time may be main reason for the difference in metastasis formation.
The growth differences between the cell lines used in this study may be related to the fact
that 435 cells may be melanoma cells rather than breast cancer cells. There is a controversy
surrounding the identity of this cell line. Originally, this cell line was described as a human
breast ductal carcinoma. Sellappan et al. demonstrated that the 435 cell line has a protein
expression profile similar to that of four other melanoma cell lines.13 In 2005 Garraway et al.,
noted the similarity of the SNP profile of MDA-MB-435 cells to that of the melanoma line
M14.14 Rae et al. have since demonstrated that the 435 and M14 cell cultures are of common
origin and suggest that the 435 cell line may have been contaminated with the M14
melanoma cell line15, which has led to the reclassification of the 435 cell line to melanoma by
some investigators. The controversy over the origin of MDA-MB-435 cells has persisted, in
part, due to conflicting reports on their cancer-like properties. This cell line has been reported
to express both epithelial markers as well as expressing proteins consistent with originating
from melanoma.13,16 As demonstrated in this work, the 435 cell line is also capable of
generating tumors when implanted into the mammary fat pad. There have been reports that
breast tumors can undergo lineage infidelity.16 As early as 1999, Nobukawa et al. described a
case of primary breast cancer differentiating into a malignant melanoma.17 If the 435 cell line
is in fact a melanoma, then this may explain the differences in growth that were observed in
this study. Implanting melanoma cells into the mammary fat pad may not allow for the full
growth potential of the cell line to be realized.
Even though there were differences observed between the cell lines used in this study, the
behavior of each cell line was consistent between strains. The incidence of metastases was
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similar between both nude and SCID strains injected with 231 cells. Some SCID mice
injected with 231 cells developed metastases in multiple lymph nodes, which may be due to
the increased immune deficiency of the SCID strain compared to the nude strain.8,18
Both the nude and SCID strains lack T cells while the SCID strain also lacks B cells.18,19
These animals retain NK cells function and possess all other components of the immune
system.18,19 Both T cells and NK cells are involved in the immune response to cancer and NK
cells can impact metastasis formation in animal models.20 Even though the nude strain
possesses B cells, these cells are typically activated through T cell dependent pathways,
leaving some deficits in B cell function in these mice.21 These similarities between the nude
and SCID strains may explain the similarities in tumor growth and metastases.
Studies have been conducted using animals with greater immune deficiencies, such as
NOD/SCID IL2R gamma null mice which have deficits in T and B cells and NK cells. These
models may allow for higher numbers of metastases, but these animals may not be the best
choice if high resolution MRI is used to monitor the lymph nodes as these animals have
underdeveloped nodes that are not detectable using MRI.9 The current work presented
suggests that a mammary fat pad xenograft model using 231 cells implanted into SCID mice
is the most appropriate for studying lymphatic metastases using high resolution MRI, due to
the low false positive and false negative rate for metastases detection based on MRI data.
Even though this combination of strain and cell line was most effectively studied using MRI,
the addition of contrast enhancement, either of the implanted cells or of the lymph nodes
prior to imaging may further enhance the detection of metastatic lymph nodes.
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Chapter 4

4

MRI Detection of Nonproliferative Tumor Cells in Lymph
Node Metastases Using Iron Oxide Particles in a Mouse
Model of Breast Cancer∗
4.1

Introduction

Magnetic resonance imaging (MRI) is a commonly used imaging method for tracking cells in
vivo in preclinical models of disease. To accomplish this cells are labeled with a contrast
agent prior to their injection or transplantation. Most cell tracking studies have used
superparamagnetic iron oxide (SPIO) nanoparticles for cell labeling. SPIO particles disturb
the static magnetic field, and this effect extends well beyond the volume of the cell, resulting
in a dramatic reduction in the T2 and T2* of nearby water molecules. T2 and T2* based
imaging methods depict SPIO labeled cells as pronounced local signal voids or hypointense
regions1. A variety of cell types have been studied using this approach. Examples include
monitoring the fate of transplanted stem/progenitor cells in myocardial infarction2,3, stroke4,
spinal cord injury5,6 and multiple sclerosis

7

and detecting the migration of dendritic cells

used in cancer immunotherapy.8–10 While most studies focus on the visualization of relatively
large numbers of cells even single iron-labeled cells can be detected in vivo by MRI.11,12
Few groups have utilized iron nanoparticles and MRI to track cancer cells. This is primarily
because the SPIO label is diluted over time in dividing cells leading to loss of signal and
therefore loss of cell detection.13 However, we, and others have shown that the retention of
iron particles in non-proliferative, or slowly cycling, cancer cells can be exploited to detect
particular cancer cell populations.14–16 Heyn et al. demonstrated that a small percentage of
brain metastatic human breast cancer cells arrest in the mouse brain and persist as distinct
signal voids in a non-proliferative state, while another population of cancer cells proliferate
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and form brain metastases.14 Townson et al. injected iron labeled metastatic melanoma cells
into the mouse liver and used MRI to show that cytotoxic chemotherapy with doxorubicin
reduced liver tumor burden but did not affect the number of non-proliferative cancer cells.15
Iron-retaining cancer cells have also been observed by MRI in melanoma xenografts
implanted subcutaneously in mice16; Magnitsky et al., demonstrated that a small, distinct
subpopulation of iron-retaining cells could be detected by flow cytometry after 20 days of in
vitro proliferation.16 These papers all demonstrated the ability to use iron nanoparticles and
MRI to image cells with a slow proliferation phenotype.
The cells these papers are targeting have been referred to as non-proliferative, quiescent,
slowly cycling or dormant. Despite the diverse nomenclature the common goal of these
studies has been to characterize a subpopulation of cancer cells that is believed to play a
critical role in tumor progression and metastasis. Several experimental metastasis models,
using a variety of cancer cell lines, show the presence of non-proliferative cancer cells, often
coexisting in a metastatic site with actively growing metastases.17–19 In breast cancer,
metastatic cancer cells can sometimes remain dormant for decades until some poorly
understood trigger causes them to proliferate and progress to clinically relevant metastases.20
In this paper we use this concept of label retention to examine this subpopulation of cancer
cells in a murine model of breast cancer metastasis. We investigate the distribution of nonproliferative cancer cells within the primary tumor and the migration of these cells to distant
lymph nodes.

4.2
4.2.1

Methods
Cell Culture and In Vitro Experiments

A green fluorescent protein (GFP) expressing transformant of the human breast cancer cell
line MDA-MB-231 (231) was used. Cells were labeled with flash red fluorescent micronsized superparamagnetic iron oxide (MPIO) particles (Excitation: 660 nm, Emission: 690
nm; Bangs Laboratories Inc., Fishers, IN). Briefly, 106 cells were plated onto T75 flasks with
normal complete media. After 24 hours, the media was replaced with a labeling media
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containing MPIO particles at a concentration of 0.049 mg Fe/ml and cells were incubated for
another 24 hours before being harvested.
To determine how MPIO particles diluted with proliferation, the cells were harvested on days
1, 2, 4, 7, 10, and 14 after addition of the labeling media (n = 3 flasks per time point). A cell
sample was taken from each flask at all time points, centrifuged onto microscopy slides and
stained for iron with Perls’ Prussian Blue (PPB). The number of iron labeled cells and the
total number of cells were counted in 5 different fields of view from each sample and the
percentage of labeled cells was determined for each timepoint.
This experiment was repeated and analyzed using flow cytometry. We collected cell samples
at days 1, 2, 4, 7, 10 and 14 (n = 3 flasks per time point). All analyses were performed using
a LSR II flow cytometer (Becton Dickinson, Mississauga, ON). The fluorescence signal of
the MPIO particles’ flash red label was obtained by excitation with a 640 nm laser and
detected using a filter with a 670 nm center and 30 nm band pass and 2 x105 events were
acquired. The iron content of cells at each timepoint was assessed by examining the amount
of fluorescence of the MPIO particles in each sample. A sample of unlabeled 231 cells was
also collected for use as a control.

4.2.2

Animal Model

5x105 unlabeled (n = 8) or MPIO labeled (n = 8) GFP positive 231 cells were injected into
the right thoracic mammary fat pad of female CB-17 SCID (CB17/Icr-Prkdcscid/IcrIcoCrl)
mice aged 6-8 weeks (Charles River Canada). Animals were imaged using MRI on days 0, 7,
14, 21 and 28 after the cell injection. Mice were sacrificed either after the appearance of
signal loss in MR images of either the ipsilateral axillary or brachial lymph nodes (5 of 8
mice in labeled group) or on day 28 after all imaging had been completed.
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4.2.3

MRI Methods

All imaging sessions were conducted using a 1.5T CV/I MRI scanner (General Electric
Medical Systems, Milwaukee, WI) along with a custom built gradient coil insert (inner
diameter = 17.5 cm, maximum gradient strength = 500 mT/m, and peak slew rate = 3000
T/m/sec) and a custom built solenoid mouse body radio-frequency (RF) coil (4cm in length
and 3cm in diameter). All images were acquired with a 3D balanced steady state free
precession (bSSFP) pulse sequence. The bSSFP sequence was chosen because it provides
very high signal to noise ratio efficiency, allowing for high-resolution image acquisitions of
the whole mouse body in reasonable scan times, and because it produces very good soft
tissue contrast, related to T2/T1. The scan parameters for bSSFP were as follows: repetition
time = 6.7 ms, echo time = 3.3 ms, flip angle = 40o, bandwidth = +/- 31.25 kHz, matrix
=300x300, field of view (FOV) = 6 cm, 0.2 mm slice thickness, 200 micron isotropic spatial
resolution, 4 signal averages (NEX), 4 RF phase cycles and scan time of 34 minutes.

4.2.4

Microscopy Methods

The left and right axillary and brachial lymph nodes and the primary tumors were removed
from the animals at necropsy. The tissues were then placed in 3.75% formaldehyde in 0.1 M
phosphate buffer overnight to fix the tissue, Some lymph nodes and tumors were then
paraffin embedded for Perls’ Prussian Blue (PPB) staining and others were placed in a
sucrose gradient over the next 3 days, followed by embedding in optimal cutting temperature
(OCT) compound for cryosectioning for fluorescence microscopy. Tissue samples were cut
into 5-µm sections for paraffin embedded samples and 16-µm for frozen samples. For
fluorescence microscopy, frozen lymph node sections were thawed and stained with DAPI
for cell nuclei. PPB staining was performed on both frozen and paraffin embedded sections.
All microscopy was performed on a Zeiss AXIO Imager (Carl Zeiss Canada Ltd.; Toronto,
ON, Canada). Fluorescence images were taken using GFP, Texas Red and DAPI filters.
Confocal fluorescence images were acquired on a Fluoview FV10i confocal microscope
(Olympus Canada Inc., Richmond Hill, ON) using a 473-nm-wavelength laser for GFP and a
635-nm-wavelength laser for Cy5.5 excitation.
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4.2.5

Image Analysis

The volume of the tumors and the left and right axillary and brachial lymph nodes were
measured by manual segmentation using the OsiriX image analysis software.21 The axillary
and brachial lymph nodes were chosen for analysis since these nodes are primarily
responsible for draining the area of the mammary fat pad where the cells were injected. The
OsiriX image analysis software21 was used to make all measurements from the images
acquired in this study. Each tumor or lymph node was segmented individually on every
image slice to create a series of regions of interest (ROI). The volume was then calculated by
using the ROI volume calculation tool available within the software package.
Tumor maps were created that distinguished between low signal intensities generated from
iron oxide particles (blue colored zone), intermediate signal intensities associated with tumor
parenchyma (green colored zone) and high signal intensities related to fluid within the tumor
(yellow colored zone). The image analysis program ImageJ22 was used to generate the cut off
values for the low and high signal intensities.
Images of single PPB stained sections were compared with composite images of 6 individual
images of PPB stained sections that were merged using the Adobe Photoshop Elements 8
software package (Adobe Systems Incorporated; San Jose, CA). Briefly, 6 images of
consecutive PPB stained tissue sections were overlaid and aligned. Areas of positive staining
were outlined in each section and a new image layer was created from the outlined areas,
colored blue and made visible above one image of the PPB stained tissue sections.
All statistical analyses were done using the Graph Pad Prism software (GraphPad Software,
Inc.; La Jolla, CA). Data were analyzed using the repeated measures Analysis of Variance
(ANOVA) test, the student T-test and the non-parametric Mann-Whitney test. P-values were
considered significant if they were less than 0.05.
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4.3
4.3.1

Results
In Vitro Iron Dilution

231 cells were labeled in vitro with MPIO particles and their iron content was assessed at
days 1, 2, 4, 7, 10, and 14 after labeling by counting PPB+ cells in stained cell samples or by
measuring the amount of red fluorescence associated with the MPIO using flow cytometry.
Cell viability after labeling (day 1 time point) was 99.2 ± 0.6%. Figure 4.1 shows the PPB
stained cell samples along with the quantification of the percentage of PPB-positive labeled
cells detected at each time point. As the cells divided the numbers of cells that contained
iron particles decreased. At days 1 and 2 after labeling 99.0 ± 0.3 % and 86.0 ± 1.4 % of cells
were labeled. The number of labeled cells decreased to 43.1 ± 1.6 % at day 4, 7.6 ± 1.6 % at
day 7, 1.0 ± 0.3 % at day 10 and 0.8 ± 0.3 % at day 14.

Figure 4.1 – Stained cell samples of MPIO labeled MDA-MB-231 cells at 1, 4, 7, 10, and
14 days after labeling. Graph of percentage of iron labeled MDA-MB-231 cells over
time.
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Similar results were observed when cells were analyzed using flow cytometry. Figure 4.2A
shows the percentage of iron-labeled cells, based on the red fluorescence associated with
MPIO, at each timepoint. At days 1 and 2 after labeling, 99.9 ± 0.1 % and 97.0 ± 0.1 % of
cells were positive for the red fluorescent particles. The number of labeled cells decreased to
45.7 ± 1.4 % at day 4, 9.5 ± 0.9 % at day 7, 2.6 ± 0.9% at day 10 and 0.5 ± 0.1 % at day 14.
Figure 4.2B shows representative dot-plots of the flow cytometry data collected for each time
point. The plots display the fluorescence of the particles in the red channel on the x-axis and
side scatter on the y-axis. Although the iron content diluted as cells proliferated, iron labeled
cells could still be detected at 14 days after labeling.
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Figure 4.2 – In vitro dilution of MPIO particles in MDA-MB-231 cells measured by flow
cytometry. (A) Graph of percentage of iron-labeled MDA-MB-231 cells over time. (B)
Plots of Flash Red fluorescence intensity (x-axis) vs. side scatter (y-axis) at day 1, 2, 4, 7,
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10 and 14 with gates shown for the labeled population (based on unlabeled control
sample).

4.3.2

MRI of Primary Tumor

Images of iron labeled tumors (Figure 4.3A) had large, obvious areas of signal loss within the
developing mass. At day 14 developing tumors appeared with mainly low signal intensity
throughout. At day 21 the MRI of tumors showed regions of low signal along with regions
of mixed, heterogeneous signal intensities. Images acquired on day 28 show that as the
tumors became larger the regions of signal loss persisted and more of the tumor mass
appeared with intermediate/high signal intensities. The images of tumors that developed
from unlabeled 231 cells (Figure 4.3B) had a different MRI appearance. These tumors had a
homogeneous, intermediate signal intensity at day 14 and became more heterogeneous in
signal as the tumors grew in size. However, regions of hypointensity, such as observed in
images of the iron-labeled tumors, were not observed in unlabeled tumors.

Figure 4.3 – Appearance of labeled and unlabeled tumors over time and corresponding
tumor color maps. (A) The MR image and color map, respectively, of a labeled tumor
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over time. (B) The MR image and color map, respectively, of an unlabeled tumor. For
color maps, Blue – below low intensity cutoff (day 7 – 255, day 14 – 288, day 21 – 301,
day 28 – 320), Green – between low intensity cutoff and high intensity cutoff (signal
intensities of 700), Yellow – above high intensity cutoff.

Tumor color maps are shown together with the MRI to assist with visualization of the tumor
borders and to highlight the three zones of signal intensities observed. The blue color
represents the regions of signal hypointensity (due to iron particles), yellow represents
regions of hyperintense signal (most likely due to fluid/necrosis) and the green color
represents the intermediate signal intensities (the bulk of the tumor mass). There is a distinct
difference in the color maps for labeled (Figure 4.3A) and unlabeled tumors (Figure 4.3B).
The percentage of the total tumor volume within each of the three zones was measured for all
tumors and is shown in Table 4.1. For iron-labeled tumors 91.4% of the tumor volume was
composed of the low signal intensity zone (blue in color map) at the first imaging timepoint
(day 7) and this decreased to 4.6% at the last imaging timepoint (day 28). In comparison, 1%
or less of the volume of unlabeled tumors fell within this zone at any timepoint. The percent
of the tumor volume within the low signal intensity zone was compared between labeled and
unlabeled groups at each time point using a Mann-Whitney test. Significant differences were
found at all times (day 7, p = 0.004; day 14, p = 0.0007; day 21, p = 0.0095; day 28, p =
0.0238). There was no significant difference in total tumor volume between the iron labeled
and unlabeled tumors at any imaging time point.
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12.1±6.1

3.4±2.4

Day 28

81.4±6.8

Day 14

Day 21

91.4 ± 15.0

Day 7

0.1 ± 0.02

0.1 ± 0.05

0.4 ± 0.5

0.5 ± 0.4

Tumors

Tumors

87.7 ± 7.5

85.2 ± 6.6

17.5 ± 6.1

7.8 ± 13.1

Tumors

Labeled

Unlabeled

Labeled

85.2 ± 5.1

88.7 ± 7.0

98.5 ± 0.6

98.2 ± 1.0

Tumors

Unlabeled

Percentage in Green Zone

Percentage in Blue Zone

above high intensity cutoff.

9.0 ± 5.1

2.7 ± 0.8

1.2 ± 1.1

0.8 ± 1.9

Tumors

Labeled

14.8 ± 5.1

11.4 ± 7.0

1.0 ± 0.8

1.3 ± 0.9

Tumors

Unlabeled

Percentage in Yellow Zone

1994.5 ± 661.1

839.9±496.2

169.9±81.9

16.3 ± 7.3

Tumors

Labeled

2574.7 ± 891.0

1003.7 ± 443.5

158.5 ± 90.4

10.2 ± 4.7

Tumors

Unlabeled

Tumor Volume (mm3)

intensity of 255), green zone is between low intensity cutoff and high intensity cutoff (signal intensity of 700), and yellow zone is

Table 4.1 – Tumor volume and percent of tumor volume in tumor color map zones. Blue zone is below low intensity cutoff (signal

2

99

100

4.3.3

Histology of Primary Tumor

Tumors were sectioned and stained for iron with PPB. Figure 4.4 depicts a tumor generated
from MPIO labeled 231 cells at day 14 after injection. Figure 4.4A, D and F show a single
16-µm PPB stained section of the tumor at increasing magnification. These sections show the
presence of iron-labeled cells within the tumor. Figure 4.4B and E are merged images of 6
consecutive PPB stained sections showing the summed iron content of all 6 sections. The
data is presented this way to illustrate the conundrum of comparing 16-µm stained tissue
sections with 200 µm MRI slices. A total of 12 tissue sections like these would have to be
merged perfectly for a true representation of the extent of iron-labeled cells contained in the
image slice. Overall, all tumors contained iron-labeled cells distributed throughout the tumor
mass.
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Figure 4.4 – PPB stained section of labeled tumor at day 14. (A) PPB stained section of
tumor lobe. (B) PPB stained section showing the iron content from 6 consecutive
sections (blue areas). (C) MR image of tumor. (D) PPB stained section of tumor from
area outlined by box in (A). (E) PPB stained section showing the iron content from 6
consecutive sections (blue areas), from area outlined by box in (B). (F) PPB stained
section of tumor from area outlined by box in (D).

4.3.4

Detection of Regions of Signal Loss in Lymph Nodes

Of particular interest was the observation of regions of signal loss in images of the draining
lymph nodes, in 6/8 mice that received MPIO labeled 231 cells. Figure 4.5 shows a
representative image of an ipsilateral axillary lymph node at day 14 with a focal region of
signal loss (A, arrow) and the corresponding PPB stained sections (B,C). The MRI and
histology showed good correspondence. In this example signal loss was observed on one side
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of the node and the most intense PPB staining was located in the same location. Fluorescence
microscopy was used to validate the presence of MPIO+ cancer cells within nodes.

Figure 4.5 – MRI and iron staining of an ipsilateral axillary lymph node 14 days after
iron-labeled breast cancer cells were implanted into the thoracic mammary fat pad in
CB17 SCID mice. (A) Cropped bSSFP image of thorax region of mouse reveals a region
of signal loss in the ipsilateral axillary node (arrow). (B) Section of lymph node stained
with Perls’ Prussian Blue for iron detection at x10 magnification shows iron positive
cells in the area of the node corresponding to the signal loss in the MR image (arrow).
(C) Iron positive area of the node at x40 magnification, where strong staining can be
seen (arrow) suggesting that cancer cells have retained iron particles after migrating to
the node.
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In Figure 4.6 an ipsilateral axillary node which showed a region of signal loss at day 28 (A)
was found to contain GFP+ cells (B) and regions of red fluorescence (C) that were colocalized (D), indicating the presence of iron-labeled cancer cells in the node. Confocal
microscopy was also performed on some lymph nodes (Figure 4.7). Tissue sections were
imaged with GFP and Cy5.5 fluorescence. Confocal image overlays of an ipsilateral axillary
lymph node at 28 days after the 231 cell injection clearly show the presence of a number of
GFP+ cells, which contain red fluorescent particles, located in the node. This data also
indicates that the cancer cells have retained the MPIO label after migrating from the tumor to
the node.

Figure 4.6 – MRI and Fluorescence microscopy of a representative SCID mouse
ipsilateral axillary lymph node 28 days after tumor cell implantation. CB17 SCID mice
were injected with GFP positive MDA-MB-231 cells labeled with red fluorescent iron
oxide particles. (A) Cropped bSSFP MRI image of the ipsilateral axillary lymph node
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shows a region of signal loss within the node (arrowhead). (B) GFP positive cancer cells
found within node correspond with (C) red fluorescent MPIO particles. (D) Overlay of
GFP fluorescent cells, red fluorescent MPIO and DAPI stain for cell nuclei. Cells that
are positive for both GFP and contain red fluorescent particles can be found within the
node, confirming the presence of iron labeled cancer cells.

Figure 4.7 – Confocal microscopy image of MPIO labeled MDA-MB-231 cells in an
ipsilateral axillary lymph node 28 days after tumor cell implantation. (A) Image at 60x
magnification. Area in white box has been enlarged (B) to show the localization of
MPIO particles (red) in the cells (green).

Fluorescence microscopy images of the lymph node sections also revealed that areas of green
and red fluorescence did not always overlap. Occasionally, red fluorescent areas were found
that correlated with DAPI staining for cell nuclei but not with areas of green fluorescence
(data not shown). This suggests that the red fluorescent iron particles can be found in other
cell types within the lymph node and may represent bystander cell uptake of iron associated
with dead tumor cells.
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Tables 4.2 and 4.3 summarize the analysis of axillary (Table 4.) and brachial (Table 4.)
lymph nodes that were examined with both MRI and microscopy. The time point that each
node was examined at is also included in these tables. Table 4. shows that 5/6 axillary lymph
nodes were positive for signal loss in MR images and that the presence of iron-labeled cells
was confirmed for all 5 nodes, with either PPB staining or fluorescence microscopy. One
axillary node did not have signal loss within it in (was MRI negative), however, fluorescence
microscopy revealed cells in the node that were both GFP and red-MPIO positive. The
sensitivity of detection of signal loss by MRI due to iron-labeled cells in the axillary nodes
was therefore 83%.

Table 4.2 – Analysis of axillary lymph nodes examined with both MRI and either PPB
staining or fluorescence microscopy (PPB = Perl’s Prussian Blue, FL = Fluorescence
Microscopy)
Axillary

Signal Loss in Positive in Microscopy (Positive Time

Lymph Node

MR Images

PPB Staining or GFP and Red- Removed
MPIO Positive Cells)

1

Yes

Yes – PPB

Day 14

2

Yes

Yes – PPB

Day 14

3

Yes

Yes – FL

Day 14

4

Yes

Yes – FL

Day 21

5

No

Yes – FL

Day 14

6

Yes

Yes – FL

Day 28

Point
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Table 4. shows that 2 of 5 brachial lymph nodes were positive for signal loss on MRI; ironlabeled cells were detected by PPB staining in both of these nodes. For 3 brachial lymph
nodes no signal loss was detected by MRI even though the fluorescence microscopy for all 3
of these nodes showed cells that were both GFP and red-MPIO positive. The sensitivity of
detection of signal loss by MRI due to iron-labeled cells in the brachial lymph node was only
40%.
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Table 4.3 – Analysis of brachial lymph nodes examined with both MRI and either PPB
staining or fluorescence microscopy (PPB = Perl’s Prussian Blue, FL = Fluorescence
Microscopy)
Brachial

Signal Loss in Positive in Microscopy (Positive Time

Lymph Node

MR Images

PPB Staining or GFP and Red- Removed
MPIO Positive Cells)

1

Yes

Yes – PPB

Day 14

2

Yes

Yes – PPB

Day 14

3

No

Yes – FL

Day 14

4

No

Yes – FL

Day 21

5

No

Yes – FL

Day 28

Point
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4.4

Discussion

The goal of this study was to investigate the potential for tracking metastatic cancer cells
using iron oxide nanoparticles and MRI. We have demonstrated that the retention of iron
particles in some cancer cells allows for their long-term tracking in vivo. Previously we
studied the fate of iron-labeled cancer cells in a model of breast cancer metastasis to the
brain14 and in a model of melanoma metastasis in the liver.15 In those models cancer cells
were delivered to the organ of interest (brain or liver) by systemic injection (intracardiac left
ventricle or intrahepatic vein) to mimic the hematogenous spread of metastatic cancer cells.
In the current study we have used an orthotopic model of breast cancer and have examined
the draining lymph nodes for metastasis.
Cell tracking with MRI and magnetic nanoparticles has not been widely applied to study
cancer cells because the iron label is diluted during cell division. Since the detection of ironlabeled cells by MRI relies on the total iron content, this means that eventually the cancer
cells will not contain enough iron to be detected as signal voids in MR images. Early in vitro
studies by Arbab et al. showed that mesenchymal stem cells, which are slowly dividing cells
in culture, retained SPIO particles for up to 7 weeks post cell labeling while iron-labeled
cancer cells (HeLa) lost their iron label by 2-3 weeks post cell labeling.23 We have previously
reported the dilution of SPIO in fast growing mouse melanoma (B16F10) cancer cells to
below MR detectable levels in only 4-5 days post cell labeling.24 In the current study both the
analysis of PPB stained cells in stained cell samples and the flow cytometric analysis showed
that in vitro by day 4 post cell labeling the number of MPIO labeled 231 cells was under
50%, and that this declined to less than 5% at day 10 post labeling. Still, at 14 days (~ 14 cell
divisions) post labeling a very small proportion of the cancer cells retained the iron label.
This finding is in agreement with a study by Magnitsky et al. who detected a small
population of MPIO-retaining human melanoma cells (~1%) at day 20 post cell labeling (~
17 cell divisions). They also used demonstrated a correlation between iron-retaining cells and
expression of JARID1B, a biological marker of slow cycling cells.16
Our in vivo MRI data also shows that not all cancer cells lose the iron label over time;
indicating that not all cancer cells undergo extensive proliferation. This is perhaps expected
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since solid tumors are known to have pronounced heterogeneity; with different
subpopulations of cancer cells (and normal stromal cells) co-existing. The list of
characteristics by which these subpopulations differ is extensive but includes cellular
morphology, receptors, enzymes, growth rates and gene expression, to name a few.25 Marked
differences in the proliferation behavior of tumor cells within a single cancer are typical.25
Some cells are nonproliferative and others are cycling but this can occur at various rates and,
at any given time, cycling cells within the tumor will be at different stages of the cell cycle.
MRI of the primary mammary fat pad tumors showed that the iron-labeled cells (blue zone)
encompass the whole tumor in the first two weeks and then, as the tumor volume increases,
makeup less of the tumor mass and appear to remain located together in one region of the
tumor.

Since sister cells have been shown to remain contiguous in solid tumors, sublines

tend to be localized regionally or zoned.26–28 Therefore, the zone of iron-retaining cells
within these tumors may reflect the presence of a specific subpopulation.
The ability to detect iron-labeled 231 cells in the ipsilateral axillary and brachial lymph nodes
after implantation of these cells in the mammary fat pad is intriguing. Since we rarely
observed GFP+ cancer cells in the nodes that were not also red fluorescent our data suggests
that there may be a relationship between the iron-retaining cell population and an invasive or
metastatic phenotype. This is the first paper to demonstrate the migration of iron-labeled
cancer cells from a primary tumor using MRI. The sensitivity of detecting signal loss by
MRI due to the presence of iron-labeled cancer cells was found to be 83% for the axillary
node and 40% for the brachial node. This is likely because the axillary nodes in the mouse
are easier to visualize in the MR images than the brachial nodes because the axillary node sits
in a more prominent fat pad, which generates very good image contrast in bSSFP images (fat
is bright, node tissue is intermediate).
Our data suggests that non-proliferative, or slowly-cycling, cancer cells can be detected by in
vivo MRI.

Non-proliferative cancer cells, sometimes referred to as dormant cells, are

believed to contribute to tumor recurrence. Clinical dormancy is reflected by relapses at
distant sites after the original primary cancer diagnosis. In some tumors, for example breast
cancer, melanoma and renal cancer, these recurrences are common and can occur many years
after diagnosis.29 Dormant cancer cells also present a substantial therapeutic problem; since
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they are quiescent they are non-responsive to current therapies which target proliferating
cells.16–18 Discerning the mechanisms that either maintain prolonged cellular dormancy or
activate dormant tumor cells to a proliferative state has been a recognized goal of scientists
worldwide. Still, relatively little is known about dormant cancer cells and studying these
cells is challenging since at the present time there are no suitable in vivo assays. It is exciting
to consider that advanced in vivo cellular imaging techniques, as described in this paper, may
be used to study the fate of distinct subpopulations of metastatic breast cancer cells within
the whole tumor in the intact mouse body.
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Chapter 5

5

Conclusions and Future Work
5.1

Conclusions

Breast cancer is a devastating disease that causes the second highest number of cancer patient
deaths in Canada.1 Many different models of breast cancer exist with new methods being
applied to the study of these models in order to gain greater insight to the progression of
tumors and the development of metastases. Advances in MRI imaging allow high-resolution
images of the entire mouse body to be acquired in a reasonable amount of time with excellent
contrast, making this modality well suited for studying breast cancer progression in vivo.
With the application of MRI to the study of breast tumor progression, the effect of the model
itself on the ability to use MRI for monitoring tumor and metastasis development needs to be
evaluated. Lymphatic metastases are an indicator of the amount of dissemination that may
have already occurred in a patient.2 There is however disagreement on the specific details of
what would be considered a metastatic lesion. Some believe that the presence of single
cancer cells in the lymph node is not a significant finding, while others argue that this highly
significant.2 More work is needed to gain a better understanding of lymphatic metastases and
the role that they play in disease progression and overall metastatic dissemination. The work
presented in this thesis hopes to provide a platform for further metastasis research and begin
to define the functional phenotype of the metastatic cell. The following sections summarize
the work completed and propose future directions that this work can follow.

5.1.1

Chapter 2

Immunodeficient mice are commonly used as recipients of human cancer cells in xenograft
models of tumor progression and metastasis. MRI is becoming a widely used tool for
noninvasively monitoring tumor growth in vivo in these preclinical investigations. In this
paper, we performed the first study of the normal MRI appearance and size of the lymph
nodes and spleen in healthy, immune-compromised (nude, SCID and NOD/SCID IL-2R null)
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and wild type (C57Bl/6) mice and examined how residual innate immunity influences the
appearance of these lymphoid organs. Our main findings were:
1. Lymph nodes in nude and less frequently in SCID mice contained a hyperintense
region visible on MRI images.
2. There were no lymph nodes that could be detected in NOD/SCID IL-2R null mice
using high-resolution MRI.
3. The MRI appearance and size of nodes in nude mice were highly variable.
4. Nodes in SCID mice were smaller than in nude or C57Bl/6 mice.
5. Over time, and with repeated MRI, the lymph node volumes changed slightly in all
strains.
Overall, the MRI appearance of the normal lymph nodes and spleen varies considerably in
the mouse strains examined in this study. This is important to recognize in order to avoid
misinterpreting MRI findings as abnormal when these strains are used in MRI studies.

5.1.2

Chapter 3

In this chapter, we compared the ability of two different tumor cell lines, MDA-MB-231 and
MDA-MB-435, to grow and metastasize to the regional lymph nodes in both nude and SCID
mice using high resolution MRI. The major findings in this study were:
1. Tumors generated from MDA-MB-231 cells were significantly larger than those from
the MDA-MB-435 cells, regardless of the strain.
2. The overall incidence of metastases was the same between both nude and SCID mice
injected with MDA-MB-231 cells; some of the SCID mice developed metastases in
more than one lymph node.
3. The high variability of nude mouse lymph nodes impact the classification of nodes as
metastatic or non-metastatic when based on volume measurements.
4. Lymph node volumes obtained from MRI data can be predictive of metastases, with
the greatest accuracy in SCID mice injected with MDA-MB-231 cells.
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In general, the strain of mouse that is used can impact the detection of lymph node
metastases when using MRI. From this study, we found that SCID mice bearing MDA-MB231 tumors would provide the best model for studying for spontaneous lymph node
metastases using MRI.

5.1.3

Chapter 4

Cell tracking with MRI and iron nanoparticles is commonly used to monitor the fate of
implanted cells in preclinical disease models. Few studies, however, have employed these
methods to study cancer cells because proliferative iron-labeled cancer cells will lose the
label as they divide. In this chapter, we evaluated the potential for retention of the iron
nanoparticle label, and resulting MRI signal, to serve as a marker for slowly dividing cancer
cells. Green fluorescent protein–transfected MDA-MB-231 breast cancer cells were labeled
with red fluorescent MPIO particles. Cells were examined in vitro at multiple time points
after labeling by staining for iron-labeled cells and by flow cytometric detection of the
fluorescent MPIO. SCID mice were implanted with MPIO-labeled or unlabeled cells in the
mammary fat pad and MRI was performed weekly until 28 days after injection.
The main findings were:
1. MPIO retaining 231 breast cancer cells can be detected both in vitro and in vivo.
2. MPIO retaining 231 cancer cells were detected in the primary tumor for up to 28 days
with MRI.
3. MPIO retaining cells were detected in the draining lymph nodes by MRI as early as
14 days and up to 28 days post cell implantation.
Our data suggest an interesting role for cell tracking with iron particles since label retention
leads to persistent signal void, allowing proliferative status to be determined. The data also
suggests that the MPIO retaining phenotype may play a role in metastatic dissemination and
survival. The most exciting finding from this study was that a specific subpopulation of
cancer cells, non-proliferative cancer cells, could be monitored in vivo over time.
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The work presented in the first two chapters of this thesis demonstrate the influence of strain
differences on lymphoid organ structure and that these differences impact growth and
metastasis in xenograft tumor models. The SCID mouse and MDA-MB-231 tumor model
from chapter 3 laid the foundation for the work in chapter 4 which demonstrated that MPIO
retaining, or slowly cycling cancer cells could be detected in vivo using cellular MRI and
were found within the draining lymph nodes of tumor bearing animals. We believe that the
model and technique described in this thesis can be used to further grow our understanding of
lymphatic metastases and the role that slowly cycling tumor cells may play in the progression
of cancer, dormancy and disease recurrence.

5.2

Future Work

The work presented in this thesis has provided answers to some questions, but has also
brought about new research questions and the opportunity to build upon what this work has
already demonstrated. The following sections describe future work that can be conducted to
further optimize the techniques described, gain a greater understanding of the properties and
behavior of the cancer cell populations and examine how the mouse strain would affect
metastasis to other organs.

5.2.1

Optimizing the Detection of MPIO Retaining Tumor Cells in MRI

Several things could be done to improve the detection of the MPIO retaining tumor cells, as
demonstrated in Chapter 4. First, it may be possible to further increase the iron content of
the implanted cancer cells by modifying the labeling techniques. This could be accomplished
by changing the concentration of the MPIO particles in culture, the duration of the labeling
phase or by using a transfection agent to increase the uptake. It would be important to not
have cells contain so much iron that it would impact the cell viability or functionality.
Another option would be to investigate MPIO particles with different coatings to see if the
coating has an effect on the uptake of the particles and their retention long term. Several
studies have also used SPIO particles to detect label retaining colorectal carcinoma and
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melanoma cells3,4, however these particles may not be as effective for tracking metastases as
they may be degraded by the cells over time,5 typically have lower iron loading per cell6 and
usually have a lower R2 value.5
Imaging parameters could also be further optimized. Phantoms containing MPIO labeled
cells that have been allowed to dilute prior to the construction of the phantoms could be used
to determine the concentration of iron per cell needed for detection or the amount of cell
division that can occur before a cell would be undetectable. These phantoms could also be
used to optimize the pulse sequence parameters to increase the sequence’s sensitivity. The
bSSFP pulse sequence that was used in this study is highly sensitive to iron. However, the
signal loss produced by iron in low concentrations can be difficult to detect. Using a different
pulse sequence that would either provide positive contrast, such as an ultrashort TE
sequence, or using other techniques that would increase the sensitivity such as T2 or T2*
maps may improve the detection of the MPIO retaining cells. Also, conducting this
experiment using a higher field strength would increase the sensitivity to the MPIO retaining
cells as well as allowing for improved image quality and potentially shorter acquisition times.

5.2.2

Demonstrating Metastasis formation from Disseminated MPIO
Labeled Cells

The work presented in chapter 4 only examined the tumor growth up to 28 days following
cell injection and animals were sacrificed after the appearance of signal loss in the lymph
nodes. The study design did not allow for development of macroscopic metastases in lymph
nodes. It would be interesting to determine if MPIO retaining cancer cells detected within
lymph nodes can go on to proliferate and form macrometastases. It would also be interesting
to compare the number of MPIO retaining cancer cells that generate metastases in the
spontaneous model to the number of cancer cells that form metastases in an experimental
model to determine if the models are consistent or if there are differences between these
types of models.
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This type of study would require that the primary tumor be removed to allow the mice to
survive longer. Alternatively a different cell line could be used if it was known to have a
slower growth rate and to form frequent metastases.

5.2.3

Correlating MPIO Retention With Standard Label Retention
Techniques and Determining Phenotype of MPIO Retaining
Tumor Cells

Many studies of stem cells and tumor initiating cells use standard label retention assays to
examine the functional properties of these cells, including BrdU, EdU and CFSE.7-11 The
retention of these compounds is considered a hallmark of cells with stem-like properties.11
Examining the way these compounds are retained and comparing them directly to MPIO
retention will allow us to determine if MPIO retention is in fact a good indicator of cells
possessing a stem-like phenotype. This can be achieved by co-labeling cells with MPIO and
one of the other compounds and comparing the dilution of both labels over time using flow
cytometry. This initial in vitro work could then be transferred to an in vivo model using the
same model described in chapter 4 to determine if the behavior of the cells remains the same
or changes in some way.
Previous studies have shown that tumor cells that retain labels, such as BrdU or EdU and
CFSE, are therapy resistant, utilize asymmetric cell division to maintain the slowly cycling
population, and are able to initiate tumors and form metastases.9 The MPIO retaining cancer
cells that we have tracked in this thesis may posses the same characteristics. These cells
could be examined in vitro to determine their phenotype.
In vitro video microscopy could be used to track the division of MPIO and BrdU labeled
cells to determine if asymmetric cell division is occurring and if it correlates with MPIO
retention.
A tumorsphere assay could also be conducted where tumor cells are sorted into MPIO
retaining and non-retaining samples using flow cytometry and then grown in serum free
conditions that promote spheroid formation.11-13 If the MPIO retaining population is able to
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consistently form spheroids, this would indicate that these cells possess stem-like
characteristics. Flow cytometry could also be used to determine if there is a particular surface
marker phenotype that would differentiate the MPIO retaining cells from the non-retaining
cells13, potentially allowing mechanisms for this population’s behavior to be discovered.
In vivo tumorigenicity assays would allow us to determine if the MPIO retaining phenotype
is tumorigenic. Limiting dilutions of the MPIO retaining and non-retaining cells would allow
the extent of the tumor forming capacity of the MPIO retaining population to be determined.

5.2.4

Effect of Treatment and Modified Gene Expression on MPIO
Retaining Cells

The MPIO retaining cancer cells that were detected in Chapter 4 in the primary tumor have
been shown by others to be resistant to chemotherapy in experimental metastasis models.14
Other studies have shown that slowly cycling cells detected by CFSE are also chemotherapy
resistant.8
The efficacy of a treatment could be evaluated in our model, allowing the treatment’s effect
on MPIO retaining cells within the primary tumor to be determined. It would be important to
determine if treatment caused only tumor debulking with retention of MPIO, depicted as a
signal void volume, that slowly declined over time due to continued cell division, or if a
greater percentage of cells will be triggered to retain MPIO by cycling much slower, creating
a signal void volume that may remain constant for the duration of the treatment. It would also
be interesting to determine if treatment would impact metastatic dissemination in our model.
Previous studies have shown resistance to therapy8,14, but have not shown if there is an
impact, whether positive or negative, on this population’s ability to disseminate to distant
sites.
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5.2.5

Examine Effect of Strain on Metastases to Other Organs and In
Different Tumor Types

In chapter 3, the focus was on the effect of the differing immune deficits of the two strains on
the ability of breast tumors to grow and metastasize to regional lymph nodes. This model
could be expanded to examine other organs such as the liver, lungs, bone and brain, which
are common sites of metastasis in breast cancer.15 We believe that mice with greater immune
deficits will exhibit higher rates of metastasis and will also have a higher occurrence of
multiple metastatic lesions in more distant organs. Xie et al. have examined the effect of
immune deficit on distant organ metastases in different tumor types and have found that this
relationship does exist.16 There are other factors in the animals’ genetic background that may
also play a role in the development of the primary tumor and metastases. Kubota et al.
compared the doubling times of different tumor cell lines in both nude and SCID mice,
finding that the doubling time on average is faster in the SCID mice, but some cell lines had
slower growth in this strain compared to the nude mice.17
However, some technical challenges do exist in trying to use our particular model with our
current system, as the volume of tumors generated from the 231 cell line becomes extremely
large by the final imaging time point and are almost too large to fit within the MR coil used
for imaging. This model would need to be modified to allow the development of metastases
in other organs without having the tumor reach a size that would impede imaging.
This could be done by either using a different cell line that has a slower growth rate or by
using a treatment model where the tumor would be resected at 4 weeks post injection to
allow for further development of organ metastases at later time points. Studies have reported
monitoring animals from 5 weeks up to 12 weeks post tumor cell injection for evidence of
metastases.16,18 By using a model that allows more long term tracking of metastasis
formation, we can gain a better understanding of the effects of the immune system on the
development of these metastases.
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Appendix C: Volumes of Individual Lymph Nodes Over Time From C57Bl/6, Nude and
SCID mice
All volumes are in mm3 for all tables shown below.
Black 6
Left

Right

Left

Right

Left

Right

Day 7
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
2.2178
2.504
2.8377
1.8571
2.1432
2.0794
2.3092
1.629

Brachial
2.1696
2.4582
2.4982
2.4449
3.1479
3.3665
3.0513
2.6968

Inguinal
2.3296
2.2203
2.1123
2.6699
2.3742
1.9985
2.607
1.9624

Popliteal
0.398
0.5922
0.7515
0.5892
0.5605
0.8479
0.6024
0.5655

Day 14
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
2.2024
2.6162
2.0261
2.0099
1.6587
2.11
2.1451
1.5238

Brachial
2.674
2.3107
2.902
2.934
1.823
4.5307
2.995
2.8896

Inguinal
1.6074
1.9087
1.4923
2.4697
2.328
1.9664
2.0374
1.8967

Popliteal
0.3561
0.3933
0.6163
0.5436
0.5735
0.6793
0.5758
0.6226

Day 28
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
2.5822
2.4314
1.8073
1.8434
1.6963
2.0634
2.2002
1.7266

Brachial
2.9707
3.2678
2.9884
2.75
2.7449
3.62
3.5129
2.9513

Inguinal
2.1843
2.3607
1.7481
1.749
2.3287
1.7651
1.9439
1.0312

Popliteal
0.6163
0.3762
0.8179
0.5288
0.8182
0.5846
0.434
0.5553
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Nude
Left

Right

Left

Right

Left

Right

Day 7
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
5.0568
6.2774
7.8572
2.5525
3.7715
1.0092
6.2044
1.7595

Brachial
4.0007
8.3018
5.1213
3.5292
3.1851
6.355
7.2901
6.7266

Inguinal
2.2279
2.1077
3.7823
2.2826
2.3061
1.9095
2.2046
2.091

Popliteal
0.3213
0.2269
0.4679
0.3198
0.4893
0.2401
0.5874
0.0068852

Day 14
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
5.0319
6.162
8.6318
2.6233
7.2069
5.8348
8.4451
4.7712

Brachial
4.873
5.3792
8.7089
3.473
4.7863
4.9423
7.6162
4.95

Inguinal
3.1424
2.6008
3.7039
3.6813
2.3177
2.5914
3.0065
3.8109

Popliteal
0.3851
0.6077
0.5405
0.4544
0.6355
0.6664
0.957
0.5157

Day 28
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
4.4632
8.1793
12.5
6.6692
6.0697
6.1943
5.9178
8.7017

Brachial
3.1495
8.0795
9.866
5.7047
2.9627
7.5757
8.2959
6.7211

Inguinal
2.6073
2.6108
5.6701
3.1452
1.8072
2.3278
4.0341
3.913

Popliteal
0.2808
0.4631
0.5078
0.8192
0.4352
0.5148
0.835
0.5685
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SCID
Left

Right

Left

Right

Left

Right

Day 7
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
0.4284
0.7287
0.3265
0.3858
0.5456
0.7052
0.4278
0.4206

Brachial
0.6212
0.7642
0.3527
0.5158
0.5379
0.6278
0.3905
0.5116

Inguinal
0.4446
0.5297
0.4678
0.2591
0.4224
0.7746
0.3145
0.4208

Popliteal
0.0832
0.1375
0.1308
0.1008
0.1525
0.2973
0.1494
0.1024

Day 14
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
0.4172
0.5497
0.4759
0.4877
0.4235
0.5185
0.3121
0.544

Brachial
0.3635
0.5674
0.2838
0.2641
0.4749
0.65
0.356
0.359

Inguinal
0.3493
0.392
0.2665
0.2213
0.3471
0.6007
0.1922
0.3247

Popliteal
0.1168
0.1338
0.1309
0.0802
0.1733
0.207
0.132
0.1017

Day 28
m1
m2
m3
m4
m1
m2
m3
m4

Axillary
0.5314
0.6994
0.4543
0.5441
1.1452
0.4262
0.4779
0.5308

Brachial
0.5794
0.4456
0.2835
0.5005
0.4635
0.5489
0.3013
0.4241

Inguinal
0.5784
0.3348
0.292
0.1702
0.4826
0.4422
0.1447
0.3553

Popliteal
0.1134
0.0854
0.0865
0.108
0.1315
0.1519
0.0947
0.1824
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